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Foreword
On behalf of the National Hepatitis C Database Steering Committee, I am very happy to introduce the 
2012 report from the National Hepatitis C Database. This is the fourth report to be produced from the 
database and is based on information up to the end of 2009 and describes the main findings from this 
data. 
The National Hepatitis C Database Steering Committee oversees the management and development 
of the database and a debt of gratitude is owed to Dr Lelia Thornton and her team in the HSE Health 
Protection Surveillance Centre for their dedication and continuing commitment to this project. It is 
hoped that the database will continue to provide an excellent resource to clinicians and researchers in 
terms of monitoring the disease progression and also to health service planners in terms of developing 
services for those infected with hepatitis C through blood and blood products. Through the Database 
Steering Committee, requests have been made by researchers and clinicians for access to the data 
which will greatly assist in helping understand more about the disease and its progression. 
Ireland’s cohort of patients who were infected through contaminated blood and blood products 
are a source of important information as most people’s date of infection is known and so therefore 
the behaviour of the virus and its impact over a period of time can be closely monitored. Therefore 
we would like to thank most sincerely all those who have given their consent to be included in the 
database and also those who have actively encouraged and continue to encourage participation 
through the hepatology units and the patient support groups. Over three quarters of those known 
to have been infected with hepatitis C through contaminated blood and blood products have their 
information included in the database which really improves the level of quality data that can be 
collected and then used when monitoring disease progression and the impact of treatment. 
The collection of this data will continue to be of vital importance in the coming years, especially with 
the advancements in treatments available to people with hepatitis C. We already know from the 
existing data that the success rate for those who have been on treatment is high among the Irish 
population. We also know that the majority of participants in the database do not show evidence of 
having serious liver disease, which  is very encouraging for patients. Factors which increase the rate of 
disease progression and disease severity include high alcohol consumption and a high BMI, both of 
which can be controlled through careful lifestyle changes. 
We look forward to continuing to work with the project over the coming years and in particular to 
analysing the data which will emerge at a time when treatments are constantly advancing and greatly 
improving the outcomes for those who are living with the disease. 
Michele Tait
Chairperson, National Hepatitis C Database Steering Committee 
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Executive Summary
Hepatitis C virus (HCV) infection is a major cause of liver disease and death throughout the world. 
Between 55% and 85% of those infected develop chronic infection. It is estimated that up to 20% of 
those with chronic infection will develop cirrhosis of the liver over 20-25 years, with 3-4% of these 
developing hepatocellular carcinoma per year. Very effective treatments for HCV are now available which 
eradicate the virus in over 50% of cases depending on the genotype. The virus is transmitted by blood 
and now occurs primarily through injecting drug use. Transfusion-related HCV infection is rare now since 
the introduction of routine screening of blood in the early 1990s.
The National Hepatitis C Database was set up in 2004 to collect data on people infected with HCV 
through the receipt of contaminated blood and blood products in Ireland. Approximately 1,700 people 
were infected through anti-D immunoglobulin, blood transfusion, blood clotting factors or treatment for 
renal disease. The purpose of the database project is to follow the natural history of infection, evaluate 
the outcomes of treatment, provide information for planning of services, and serve as a resource for 
research. This report is based on the fourth round of data collection and includes data on database 
participants up to the end of 2009.
Main findings
Profile of participants
•  There are 1316 database participants, a participation rate of 77%.
•   The source of infection was anti-D immunoglobulin in 61%, blood transfusion or treatment for 
renal disease in 26% and blood clotting factors in 13%.
•  The average age at last follow-up was 57 years.
•  The average time interval from infection to last follow-up was 30 years.
Hepatitis C status
•  48% of participants were still chronically infected at the time of last testing.
•   The spontaneous viral clearance rate in this population is between 19% and 36% (having taken 
account of those who died before RNA testing, and allowing for the possibility that some 
participants may have had false positive screening test results).
•   Females were more likely to have cleared the virus spontaneously.
•   The most common genotype is genotype 1 (76%), followed by genotype 3 (18%).
Alcohol consumption
•   Alcohol consumption in excess of recommended levels was recorded for 15% of those chronically 
infected. This was higher in males and in younger people.
Outcomes
Cirrhosis
•   Cirrhosis had developed in 137 participants (17%) who ever had chronic infection, at an average 
duration of infection of 24 years and an average age of 53 years. This was an increase of 26 cases 
since the last round of data collection.
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•   Alcohol consumption was the biggest determinant of risk of cirrhosis in those with chronic infection. 
Other factors associated with cirrhosis were duration of infection, male gender and genotype 3 
infection.
•   Participants infected through blood transfusions or treatment for renal disease were more likely to 
have cirrhosis that those in the anti-D cohort. 
•   There were no cases of cirrhosis in participants who did not become chronically infected. 
Hepatocellular carcinoma (HCC)/liver cancer
•   HCC had developed in 32 (4%) of those who ever had chronic infection, at an average duration of 
infection of 28 years and an average age of 63 years. The prevalence was significantly higher in males 
than in females. Participants infected through transfusions or treatment for renal disease or through 
blood clotting factors were more likely to have HCC that those in the anti-D cohort.
•   This was an increase of 9 in the number of HCC cases since the last round of data collection.
•   There were no cases of HCC in participants who did not become chronically infected.
Liver biopsies
•   Note: Liver biopsies have been infrequently carried out in recent years so for some participants their 
last biopsy may have been many years ago.
•   Moderate or severe inflammation on the last liver biopsy was recorded in 26% of ever chronically 
infected participants compared with 1% of those who did not develop chronic infection. This 
proportion was higher (34%) in those infected through blood transfusion or treatment for renal 
disease.
•   A high fibrosis score on the last liver biopsy was recorded in 19% of ever chronically infected 
participants compared with 4% of those who never developed chronic infection. This proportion was 
higher (32%) in those infected through blood transfusion or treatment for renal disease.
•   Factors associated with having a high fibrosis score were male gender, older age, genotype 3 infection 
and high alcohol consumption.
Deaths
•   By latest follow-up, 212 participants (16%) had died, an additional 25 deaths since the previous round 
of data collection. The proportion who had died was higher in those who ever had chronic infection 
(18%) than in those who did not develop chronic infection (6%).
•   Those who had been chronically infected but had cleared the virus (mostly through treatment) had a 
lower mortality rate at 4%.
•   Death from liver disease occurred in 55 participants (4%), most of whom had developed chronic 
infection or had no RNA results in their charts (and had died before RNA testing began).
•   High alcohol intake was a highly significant predictor of liver-related mortality. Liver-related mortality 
was also higher in males and those infected through blood transfusions or blood clotting factors.
Severe liver disease - summary measure
•   Using a summary measure of “severe liver disease”, 31% of participants with current chronic infection 
were classified as having severe liver disease, compared with 2% of those who were never chronically 
infected.
•   The determinants of having severe liver disease were high alcohol intake, older age at last follow-up, 
male gender, longer duration of infection and HCV genotype 3.
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•   Participants infected through blood transfusions/treatment for renal disease and those infected 
through blood clotting factors were more likely to have severe liver disease compared with the anti-D 
cohort.
•   The most important factor in disease progression was alcohol intake. Participants who had high 
alcohol intake had more than 5 times higher odds of having severe liver disease compared to those 
without.  
Anti-viral treatment
•   Forty two percent of chronically infected participants had received at least one course of anti-viral 
treatment.
•   Twenty four percent of all treatment courses were stopped early due to side-effects.
•   Younger participants, those infected in the 1991-1994 anti-D outbreak, or through blood transfusion 
or clotting factors, those with high fibrosis scores and those with genotype 2 or 3 infections were 
more likely to have been treated.
•   Among those whose first treatment was with pegylated interferon and ribavirin, a sustained 
virological response was achieved for 73% of genotype 2 or 3 participants compared with 41% of 
genotype 1 participants.
Liver transplants
•   Nineteen database participants had received a liver transplant. The average age at transplant was 
53 years and the average duration of infection was 29 years.
•   All those tested post-transplant remained RNA positive.
•   Five of the liver transplant recipients have since died.
Focus on different patient groups
•   Detailed descriptions of the 3 patient groups (anti-D, blood transfusion/renal and blood clotting 
factors), with information on their health outcomes and treatment, are provided in individual 
sections in Chapter 4.
Service usage
•   Most participants had attended their hepatology unit in the previous 2 years (76%), this figure being 
higher (88%) for those with chronic infection.
•   The specialist services other than hepatology that were most commonly used by chronically 
infected participants were haematology, endocrinology, rheumatology and psychiatry/psychology/
counselling.
Conclusion
This report describes the current health of a large group of people who were infected with hepatitis C virus 
through the administration of blood or blood products many years ago. Almost half of this population still 
have chronic hepatitis C infection. Despite this, the majority do not have evidence of serious liver disease 
after an average of more than 30 years of infection. However, the findings of this latest round of data 
collection have demonstrated further progression of liver disease in a small number of participants
It is hoped that there may be more active recording of up to date information on alcohol consumption and 
BMI in the patient medical notes by the time of the next period of data collection. We hope to be able to 
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report on genetic and metabolic factors affecting disease progression in the next report from the database. The 
recent addition of protease inhibitors into the management of genotype 1 infection will be captured in the next 
round of data collection and reported in the next report.  
The participation rate in the database project is high at 77%. The ongoing support of participants, support groups 
and health professionals is essential to the success of this work. Eligible people who are not yet participants in the 
database may join at any time by contacting their hepatology unit. The database project team invites participants, 
health professionals and researchers to contact us with suggestions for further development or improvement of the 
database, and requests for information from the database. 
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Table 1. Summary of main outcomes by hepatitis C RNA status for all participants
Outcomes
All
(n=1316)
Ever 
chronically 
infected *  
(n=815)   
Currently 
chronically 
infected 
(n=605)
Chronically 
infected in 
past (n=210)
Never 
chronically 
infected † 
(n=451)
No RNA 
results (n=50)
  Num % Num % Num % Num % Num % Num %
Signs of liver disease 187 14.2 175 21.5 149 24.6 26 12.4 5 1.1 7 14.0
Cirrhosis 142 10.8 137 16.8 118 19.5 19 9.1 0 0.0 5 10.0
Liver tumours or 
HCC
34 2.6 32 3.9 31 5.1 1 0.5 0 0.0 2 4.0
High fibrosis score 
on biopsy ‡ 167 12.7 160 19.6 125 20.7 35 16.7 4 0.9 3 6.0
Deceased 212 16.1 145 17.8 137 22.6 8 3.8 26 5.8 41 82.0
Died from liver 
disease § 55 4.2 45 5.6 43 7.2 2 1.0 2 0.4 8 17.4
*  At least one positive hepatitis C RNA result – testing carried out sometime after infection so this is a good indicator of chronic infection
†  Positive or indeterminate line-immunoassay results (RIBA/INNO-LIA) or positive/weak positive EIA/ELISA results, RNA tests done but never 
tested RNA positive. These participants cleared the hepatitis C virus spontaneously and are likely to have done so within a year of infection
‡  Ever had a fibrosis score of 3 or 4 on biopsy scored from 0 to 4 or a fibrosis score of 4, 5 or 6 on biopsy scored from 0 to 6. Denominator is 
all participants (includes those who did not have biopsy results). The proportion of chronically infected participants who had biopsies was 
significantly higher than that for participants who did not become chronically infected.
§  Liver-related disease directly caused death. Denominator for this is all participants minus the 13 participants whose cause of death was not 
available (n=1303)
Table 2. Current RNA status (this includes the last known status of deceased participants) for all participants
Final status All (n=1266) Ever chronically infected* (n=815)
  Num % Num %
Currently chronically infected† 605 47.8 605 74.2
Treated and cleared virus 176 13.9 176 21.6
Cleared virus without 
treatment ‡ 485 38.3 34 4.2
Had positive confirmatory 
antibody results § 225 17.8 34 4.2
Not confirmed positive װ 260 20.5    
* At least one positive hepatitis C RNA result 
† Hepatitis C RNA positive at most recent test (includes participants who have died)
‡ Hepatitis C antibody positive, never treated
§ Positive line-immunoassay results (RIBA/INNO-LIA) results
װ positive/weak positive EIA/ELISA results or indeterminate line-immunoassay results, RNA tests done but never tested RNA positive.
Note: Participants with no RNA results in their charts were omitted from this table as there is no way of determining their RNA status (n=50)
Summary tables
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Table 3. Summary of main outcomes by hepatitis C RNA status for all anti-D participants
Outcomes All * (n=808)
Ever chronically 
infected (n=432)
Currently 
chronically 
infected (n=335)
Chronically 
infected in past 
(n=97)
Never chronically 
infected (n=366)
  Num % Num % Num % Num % Num %
Signs of liver disease 64 7.9 60 13.9 51 15.2 9 9.3 3 0.8
Cirrhosis 50 6.2 49 11.3 42 12.5 7 7.2 0 0.0
Liver tumours or HCC 5 0.6 5 1.2 5 1.5 0 0.0 0 0.0
High fibrosis score on 
biopsy 76 9.4 73 16.9 62 18.5 11 11.3 2 0.6
Deceased 56 6.9 37 8.6 35 10.5 2 2.1 18 4.9
Died from liver dis-
ease † 13 1.6 11 2.6 11 3.3 0 0.0 1 0.3
* There were no RNA results in the charts of 10 participants. These are included under all, but not under ever or never chronically infected 
† Denominator for this is all participants minus the three participants whose cause of death was not available (n=805)
Table 4. Current RNA status (this includes the last known status of deceased participants) for all anti-D 
participants
Final status All (n=798) Ever chronically infected (n=432)
  Num % Num %
Currently chronically infected 335 42.0 335 77.6
Treated and cleared virus 76 9.5 76 17.6
Cleared virus without treatment 387 48.5 21 4.9
Had positive confirmatory 
antibody results 167 20.9 21 4.9
Not confirmed positive 220 27.6    
Note: Participants with no RNA results in their charts were omitted from this table as there is no way of determining their RNA status (n=10)
Table 5. Summary of main outcomes by hepatitis C RNA status for anti-D participants infected between 1977 
and 1979
Outcomes All * (n=679) Ever chronically infected (n=378)
Currently chroni-
cally infected 
(n=320)
Chronically 
infected in past 
(n=58)
Never 
chronically 
infected (n=295)
  Num % Num % Num % Num % Num %
Signs of liver disease 57 8.4 53 14.0 47 14.7 6 10.3 3 1.0
Cirrhosis 45 6.6 44 11.6 39 12.2 5 8.6 0 0.0
Liver tumours or HCC 5 0.7 5 1.3 5 1.6 0 0.0 0 0.0
High fibrosis score 
on biopsy 73 10.8 70 18.5 61 19.1 9 15.5 2 0.7
Deceased 54 8.0 36 9.5 35 10.9 1 1.7 17 5.8
Died from liver 
disease † 13 1.9 11 2.9 11 3.5 0 0.0 1 0.3
* There were no RNA results in the charts of 6 participants. These are included under all, but not under ever or never chronically infected 
† Denominator for this is all participants minus the three participants whose cause of death was not available (n=676)
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Table 6. Current RNA status (this includes the last known status of deceased participants) for anti-D 
participants infected between 1977 and 1979
Final status All (n=673) Ever chronically infected (n=378)
  Num % Num %
Currently chronically infected 320 47.6 320 84.7
Treated and cleared virus 40 5.9 40 10.6
Cleared virus without 
treatment
313 46.5 18 4.8
Had positive confirmatory 
antibody results
154 22.9 18 4.8
Not confirmed positive 159 23.6    
Note: Participants with no RNA results in their charts were omitted from this table as there is no way of determining their RNA status (n=6). 
Table 7. Summary of main outcomes by hepatitis C RNA status for anti-D participants infected between 1991 
and 1994
Outcomes All * (n=73)
Ever chronically 
infected (n=38)
Currently 
chronically 
infected (n=5)
Chronically 
infected in past 
(n=33)
Never chronically 
infected (n=31)
  Num % Num % Num % Num % Num %
Signs of liver disease 5 6.9 5 13.2 3 60.0 2 6.1 0 0.0
Cirrhosis 3 4.1 3 7.9 2 40.0 1 3.0 0 0.0
Liver tumours or HCC 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
High fibrosis score on biopsy 2 2.7 2 5.3 1 20.0 1 3.0 0 0.0
Deceased 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Died from liver disease 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
* There were no RNA results in the charts of 4 participants. These are included under all, but not under ever or never chronically infected
Note: 5 participants who were infected during this anti-D outbreak period had non-outbreak genotypes and were excluded from this table
Table 8. Current RNA status (this includes the last known status of deceased participants) for anti-D 
participants infected between 1991 and 1994
Final status All (n=69) Ever chronically infected* (n=38)
  Num % Num %
Currently chronically infected 5 7.3 5 13.2
Treated and cleared virus 30 43.5 30 79.0
Cleared virus without treatment 34 49.3 3 7.9
Had positive confirmatory 
antibody results 7 10.1 3 7.9
Not confirmed positive 27 39.1    
* Participants with no RNA results in their charts were omitted from this table as there is no way of determining their RNA status (n=4). Five 
participants who were infected during this anti-D outbreak period had non-outbreak genotypes and were also excluded from this table
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Table 9. Summary of main outcomes by hepatitis C RNA status for blood transfusion/renal participants
Outcomes All *(n=337)
Ever chronically 
infected (n=273)
Currently chroni-
cally infected 
(n=194)
Chronically 
infected in past 
(n=79)
Never 
chronically 
infected (n=61)
  Num % Num % Num % Num % Num %
Signs of liver disease 86 25.5 83 30.4 70 36.1 13 16.5 2 3.3
Cirrhosis 71 21.1 70 25.6 58 29.9 12 15.2 0 0.0
Liver tumours or HCC 21 6.2 21 7.7 20 10.3 1 1.3 0 0.0
High fibrosis score on 
biopsy
82 24.3 78 28.6 56 28.9 22 27.9 2 3.3
Deceased 85 25.2 75 27.5 72 37.1 3 3.8 7 11.5
Died from liver 
disease † 22 6.6 21 7.8 19 10.1 2 2.5 1 1.6
*  There were no RNA results in the charts of 3 participants (all deceased). These are included under all, but not under ever or never chronically 
infected 
† Denominator for this is all participants minus the six participants whose cause of death was not available (n=331)
Table 10. Current RNA status (this includes the last known status of deceased participants) for blood 
transfusion/renal participants
Final status All (n=334) Ever chronically infected (n=273)
  Num % Num %
Currently chronically infected 194 58.1 194 71.1
Treated and cleared virus 71 21.3 71 26.0
Cleared virus without 
treatment 69 20.7 8 2.9
Had positive confirmatory 
antibody results 34 10.2 8 2.9
Not confirmed positive 35 10.5    
Note: Participants with no RNA results in their charts were omitted from this table as there is no way of determining their RNA status (n=3)
Table 11. Summary of main outcomes by hepatitis C RNA status for blood clotting factor participants
Outcomes All (n=165)
Ever 
chronically 
infected 
(n=107)
Currently 
chronically 
infected (n=73)
Chronically 
infected in 
past (n=34)
Never chroni-
cally infected 
(n=21)
No RNA re-
sults (n=37)
  Num % Num % Num % Num % Num % Num %
Signs of liver disease 36 21.8 31 29.0 27 37.0 4 11.8 0 0.0 5 13.5
Cirrhosis 20 12.1 17 15.9 17 23.3 0 0.0 0 0.0 3 8.1
Liver tumours or 
HCC 8 4.9 6 5.6 6 8.2 0 0.0 0 0.0 2 5.4
High fibrosis score 
on biopsy 9 5.5 9 8.4 7 9.6 2 5.9 0 0.0 0 0.0
Deceased 70 42.4 32 29.9 29 39.7 3 8.8 1 4.8 37 100.0
Died from liver 
disease * 19 11.8 12 11.3 12 16.4 0 0.0 0 0.0 7 20.6
* Denominator for this is all participants minus the four participants whose cause of death was not available (n=161)
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Table 12. Current RNA status (this includes the last known status of deceased participants) for blood clotting 
factor participants
Final status All (n=128) Ever chronically infected (n=107)
  Num % Num %
Currently chronically infected 73 57.0 73 68.2
Treated and cleared virus 29 22.7 29 27.1
Cleared virus without treatment 26 20.3 5 4.7
Had positive confirmatory antibody results 22 17.2 5 4.7
Not confirmed positive 4 3.1    
Note: Participants with no RNA results in their charts were omitted from this table as there is no way of determining their RNA status (n=37)
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Figure 1. Summary of RNA status, and disease progression by RNA status, for all participants and by source of 
infection  
Note: 50 participants had no RNA results in their charts. Of these, 37 were infected through contaminated blood clotting factors. These 
participants were similar to the participants who became chronically infected in terms of outcomes. Six participants had a source of infection 
other than those shown.
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Chronic hepatitis C infection is a major cause of chronic liver disease and death throughout the world.1 
Approximately 3% of the world’s population is infected with hepatitis C virus (HCV).2 Hepatitis C infection is caused 
by an RNA virus that was first identified in 1989.3 Six distinct but related genotypes and multiple subtypes have 
been identified. In Western Europe genotypes 1a and 1b are most common, followed by genotypes 2 and 3.4
HCV is transmitted by blood and now occurs primarily through injecting drug use, and less frequently through sex 
with an infected partner, occupational exposure, and maternal-fetal transmission. In some cases no risk factors can 
be identified.4,5 Transfusion-related HCV infection is rare now since the introduction of routine screening of blood for 
HCV antibodies in the early 1990s.
Acute HCV infection, in general, is relatively mild with only 20-30% of infected persons developing symptoms or 
clinically evident acute infection.2 In most persons who become infected with HCV, viremia persists. Chronic HCV 
infection is marked by persistence of HCV RNA for at least 6 months after onset of infection. Spontaneous resolution 
after 6 or 12 months of infection is unusual.3 Between 55% and 85% of those infected develop chronic infection6, the 
lower end of the range being accounted for mainly by women, particularly young women.7,8
Chronically infected people are at risk for progressive liver disease characterised by hepatocellular inflammation, 
hepatic fibrosis, cirrhosis and hepatocellular carcinoma (HCC).6 These complications develop only in a proportion 
of patients and only after many years or decades of infection.3 It has been estimated that up to 20% of chronically 
infected individuals will develop cirrhosis of the liver over a 20 to 25 year period, and that, of patients with 
cirrhosis, approximately 3% to 4% will develop HCC per year.9 Factors that have been shown to be associated with 
progression of liver fibrosis include older age at infection, male gender, genetic factors, metabolic factors (steatosis, 
diabetes and obesity), co-infection with human immunodeficiency virus (HIV) or hepatitis B, duration of infection, 
and alcohol intake.1,4,6,9
Chronic HCV infection has been associated with several extrahepatic manifestations including essential mixed 
cryoglobulinemia, B-cell non-Hodgkin lymphoma, glomerulonephritis, seronegative arthritis, keratoconjunctivitis 
sicca and sialadenitis, lichen planus, neuropathies and neurological conditions including cognitive disorders and 
porphyria cutanea tarda.3
Very effective treatments for hepatitis C are now available. The standard of care for the past decade has been a 
combination of pegylated interferon and ribavirin for 24 to 48 weeks, depending on the genotype. This has resulted 
in a successful response to treatment in more than 75% of patients with genotypes 2 and 3 HCV infection, and 
40-50% of those with genotype 1.10,11  In recent years, directly acting antiviral agents have been developed. Two 
of these are the protease inhibitors telaprevir and boceprevir which, when used in combination with pegylated 
interferon and ribavirin in genotype 1 patients, have greatly improved sustained virological response rates in both 
treatment naïve patients and patients who have had previous virological failure on treatment.12, 13
Chapter 1  Hepatitis C Virus Infection
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Hepatitis C infection
Hepatitis C natural history
Chronic infection
 (55-85%)
Hepatitis C RNA still
detectable. Long-term
hepatitis C infection
Liver fibrosis
Acute infection
followed by viral
clearance
(15-45%)
Hepatitis C RNA no
longer detectable.
6 months
Cirrhosis of the
liver
Liver failure or
hepatocellular
carcinoma
Mild
Moderate
Advanced
20 - 40 years
Factors increasing rate of disease
progression and disease severity
High alcohol consumption
High BMI, insulin resistance or
Steatohepatitis
Male gender
Older age
Co-infection with HIV
Co-infection with hepatitis B
Factors decreasing or halting disease
progression and disease severity
Anti-viral treatment
Liver transplant (temporary)
At risk for
Figure 2. Summary of natural history of hepatitis C infection
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Background to the database
The National Hepatitis C Database was set up in 2004 by the HSE-Health Protection Surveillance Centre (HPSC) in 
association with eight specialist hepatology units to collect data on persons who were identified as being infected 
with HCV through the receipt of contaminated blood and blood products in Ireland. 
These include women infected through anti-D immunoglobulin, recipients of blood transfusion, people with 
haemophilia and other blood clotting disorders and people who received treatment for renal disease.14 Specialist 
hepatology services were set up in eight designated hospitals to provide services for this group, which numbers 
approximately 1,700 people. Those infected are also entitled to a range of additional hospital and primary care 
services under the Health (Amendment) Act, 1996 (HAA). 
Approval for this project was obtained from the ethics committees of all eight hospitals and from the Office of 
the Data Protection Commissioner. The development and management of the database project is overseen by a 
Steering Committee (appendix A). A Scientific and Technical Group supports and advises HPSC on the scientific and 
technical development of the database (appendix B).
The objectives of the database are: 
1. To follow the natural history of infection in people infected through blood and blood products
2. To evaluate the impact of various host factors on the progression of the disease
3. To evaluate the outcomes of treatment
4. To monitor the uptake of services
5. To provide information for the planning and evaluation of health services
6. To serve as a resource for future research into hepatitis C
Baseline data were collected in 2005 and 2006 and included all relevant data from the date of diagnosis on all 
consented participants. A baseline report15 describing these data was published in October 2007. Two follow-up 
reports have been published since baseline data collection, in 200916 and 2010.17 This is the third follow-up report 
and includes information on all participants up to the end of 2009. All reports and patient newsletters are available 
through the hepatology units, patient support groups, hepatitis C liaison officers and on the database website 
(www.hcvdatabase.ie).
Database population
Any person (alive or dead) who contracted HCV infection through the administration of blood or blood products 
within the state is eligible to be included in the database. These include women infected through anti-D 
immunoglobulin, recipients of blood transfusion, people with haemophilia and other blood clotting disorders and 
people who received treatment for renal disease. Eligible patients were identified by the eight specialist hepatology 
units.15
For the purpose of this database, hepatitis C infection is defined as the detection of hepatitis C specific antibodies 
or the detection of hepatitis C nucleic acid. This includes all those who are ELISA (enzyme linked immunosorbent 
assay)/EIA (enzyme immunoassay) positive or weak positive, recombinant immunoblot assay (RIBA)/INNO-LIA 
positive or indeterminate, or hepatitis C polymerase chain reaction (PCR)/RNA positive. 
Information is collected only on eligible people who consent to participate in the database and on eligible 
participants who have died. Relatives of deceased people are entitled to refuse participation and no data are 
collected on those who refused to participate in the database when they were alive. 
Chapter 2  National Hepatitis C Database
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Source of data
Information is gathered from the participants’ medical records (hospital charts) in the eight hepatology units and is 
updated on a regular basis. No direct contact is made with any participant. No names or addresses are recorded in 
the database. 
Data security
The database was built using MS SQL server 2000. It is physically located in a secure computer room in HPSC with 
access strictly limited to key technical support staff. Access to the database is secured by a combination of network, 
SQL server and MS Access security permissions. All paper forms are stored in a locked cabinet in HPSC. 
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Chapter 3 Follow-up Data Collection to 
end 2009 
 
Data Collection
The fourth round of data collection began in September 2010 capturing data on patients up to 31st December 2009. 
Data are extracted from the participants’ medical notes by a HPSC research nurse. Information collected includes 
clinical, demographic and lifestyle data  which has been added to the participants’ medical records between the 
date of last data collection (up to the end of 2008) and the date of follow-up data collection (up to 31st December 
2009). Data were entered into the database by a surveillance assistant. Double entry was used to maximise 
accuracy. In order to continuously improve the information held on participants, additional data fields were included 
in the latest follow-up data collection form. These included more detailed results of haematology and biochemistry 
tests, fibroscans and other diagnostic tests. More details were also recorded on side effects of antiviral treatment. 
Recruitment of new participants 
Recruitment of new participants to the database is ongoing and new participants are welcome to join at any time. 
These would include those people who did not consent to database participation when first invited to do so in 2004, 
and those newly identified as eligible since 2004. Patients are given the opportunity to consent at their hospital 
appointments where they are given further information by staff on the database. This has proven to be a successful 
method of encouraging patients who have not yet consented to consider participating in the database. Those who 
refused to consent at any time are not asked again. The patient support groups also encourage their members to 
participate through their newsletters and meetings.
There is a small number of people living abroad (approximately 25, personal communication, Michelle Tait HSE), 
who meet the eligibility criteria for the database but who do not attend a clinical service in Ireland. They are not 
currently included in the database due to the difficulties that would arise in terms of data collection, data quality, 
confidentiality and consent.
Assumptions
Various assumptions were made where data were missing. These related mainly to the year of infection. These 
assumptions were:
•   Anti-D: If the person had received anti-D on multiple occasions, and one of these was the year of an outbreak 
period, i.e. 1977-1979 or 1991-1994, this year was taken as the year of infection. If none of the years fell into either of 
the outbreak periods, the earliest year that anti-D had been administered was used as the year of infection.
•   Blood transfusion/treatment for renal disease: If the person had received multiple blood transfusions and none 
of them had been identified as being infectious, the earliest transfusion year was taken as the year of infection. 
Where the person had also been on dialysis for extended periods of time, the year of starting dialysis or of first 
blood transfusion, whichever was the earlier, was used as an estimate of the year of infection.
•   Clotting factors: For people with haemophilia and other blood clotting disorders, if the year of infection was not 
available, the year that the patient first received clotting factors was used as a proxy for the year of infection. 
Where the year of infection and the year when first factor was administered were missing, then the year of 
diagnosis of haemophilia was used as the year of infection. 
•   Where precise day or month were missing from dates (e.g. date of infection), the year of infection was converted 
to 02/07/YYYY, where YYYY was the year of infection and 02/07 was the midpoint of the year. All ages calculated 
were truncated and all durations were rounded based on the outcome of the calculation. 
Estimating dates of cirrhosis and hepatocellular carcinoma (HCC)/liver cancer
Variables were created to indicate if participants had cirrhosis or liver cancer on biopsy or mentioned elsewhere in 
their medical charts or death certificates. Estimated dates of onset were generated for both conditions, but these 
were approximate. If multiple biopsies, ultrasounds or CT scans were done, the midpoint between the first positive 
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and last negative date was used. Where cirrhosis or liver cancer was first mentioned on death certificates, the 
midpoint between the date of death and last negative diagnostic test or last visit to the hepatology unit was used. 
Otherwise the earliest date mentioned in relation to a diagnosis of cirrhosis or liver cancer was taken.
Estimating duration of hepatitis C ribonucleic acid (RNA) positivity
All RNA results were recorded for each participant. A variable was created to record the duration of RNA positivity in 
years for all participants who ever tested RNA positive. The following rules were used:
•   If a participant remained RNA positive when last tested and was still alive, the duration of RNA positivity was 
calculated as their date of last visit minus their date of infection. If they were deceased, their date of death minus 
their date of infection was used.
•   For participants who had tested RNA positive and cleared the virus, the duration of RNA positivity was calculated 
as the midpoint between the first negative and last positive result minus their date of infection.
Coding of death certificates
Death certificates were collected on deceased participants from the General Register Office (GRO). This was done 
by the research nurse, acting on behalf of the hepatology unit. No named data were brought to HPSC. The cause 
of death was coded using the World Health Organization (WHO) ICD-10 coding format. Analysis was done on the 
underlying cause of death as defined by the ICD system. 
The cause of death was further classified using the following broad categories:
•   Death directly caused by liver-related disease
•   Death not directly caused by liver-related disease, but liver-disease or hepatitis C listed as a contributing condition 
on the death certificate
•   Death was not liver-related
Death was considered to be directly caused by liver-related disease in the following situations:
If hepatocellular carcinoma or end-stage liver disease (varices, ascites, liver failure or hepatic encephalopathy) were 
listed as any of the causes of death in section I of the death certificate
Or if liver disease was not specified as end-stage (e.g. cirrhosis) but the sequence of causes of death on the 
certificate suggested death was due to liver disease, 
Or if liver disease was coded as the underlying and only cause of death.
The classification of all deaths was carried out by a consultant hepatologist and a medical epidemiologist, blinded 
to the hepatitis C immunoblot or RNA status.
Long-term medications
Long term medications mentioned in the patient’s chart are recorded in the database and were coded using the 
Anatomical Therapeutic Chemical (ATC) classification system. This is a standardised coding system, controlled by 
the World Health Organization, and is based on the organ or system on which the drug acts. 
Liver biopsies
Different scoring systems were used to stage and grade the hepatitis C liver biopsies in the different hepatology 
units (appendix D):
•   Knodell system: 18 fibrosis scored from 0-4 
•   Modified Knodell system, 19,20 also known as the Ishak or the modified HAI system: fibrosis scored from 0-6 
•   Scheuer system: 21 fibrosis scored from 0-4
•   International Group of Hepatopathologists system: fibrosis scored from 0-4 
For some of the analyses, the biopsies scored from 0 to 6 were converted to 0 to 4 scores so that all scored biopsies 
could be considered together. The following conversions were used: 0=0, 1=1, 2=1, 3=2, 4=3, 5=3 and 6=4. 
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Data analysis
Data analysis was done using Business Objects, Microsoft Access 2007, Microsoft Excel 2007 and Stata/SE 
version 10.0. Either Pearson’s Chi-square or the Wald test, with corresponding probability value (P-value) and 
95% confidence intervals were used to test for differences between odds of a given outcome in logistic regression 
analysis. Poisson regression was used to examine survival since infection with HCV. All statistical tests were 2-tailed 
and a p-value of < 0.05 was taken as statistically significant.
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Chapter 4  Main Findings
Participation rates and representativeness of the database cohort
The overall participation rate in the database is now 77%, including people who have died, and the consent rate is 
74% (figure 3). Thirteen people have been added to the database since the last round of data collection, bringing the 
total number of participants to 1,316. The new database participants include six new consents and seven people who 
are newly deceased or newly identified as deceased. Figure 3 details the response rate by source of infection.
Eligible people who died before start of
study
159 (9.3%)
Eligible people who were living when the
study started
1556 (90.7%)
Consented
1153 (74.1%)
No response
347 (22.3%)
Refused
57 (3.7%)
Overall cohort of people who had consented or had died
1329 (77.5% of total eligible)
Total database cohort
at year 3 of follow up
1316 (76.7%)
Charts missing
  13 (all RIP)
Non responders who died
after the study started
17
Source of infection
Response rates and summary of cohort (n=1715)
Anti-D
n=808, 61.4%
Blood transfusion/treatment for
renal disease
n=337, 25.6%
Blood clotting
factors
n=165, 12.5%
Other
n=6, 0.5%
Figure 3. Participation rates and database cohort
Note:  Source of infection = “Other” includes participants infected through vertical or sexual contact with people with state-acquired infection. 
The anti-D group includes 679 participants infected in the 1977-1979 outbreak, 73 participants infected in the 1991-1994 outbreak, 51 
participants infected during non outbreak years and 5 participants infected in outbreak years, but who had a different HCV genotype to the 
outbreak genotype.
Although we do not have patient-based data on source of infection or gender for non-participants, the hepatology 
units provide us with summary data to enable us to assess how representative the database population is of the 
entire eligible population. Database participation varied with age and RNA status, with older people and those 
who became chronically infected more likely to participate. This difference was statistically significant and was also 
evident when deceased patients were excluded from the analysis.
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Description of database population
RNA results
RNA tests are used to test for circulating virus. Positive results indicate current infection. In general, ELISA/EIA 
tests are used as screening tests for HCV antibodies, and line-immunoassay tests (e.g. RIBA/INNO-LIA) are used 
to confirm positive antibody results. The combination of a positive HCV antibody result and a negative RNA result 
indicates past infection.
As the vast majority of participants were diagnosed some years after infection, ever testing RNA positive was found 
to be an excellent indicator of chronic long-term infection. Throughout this report, we treat participants who ever 
tested RNA positive as having been chronically infected with HCV and these participants are the primary focus when 
looking at clinical outcomes and disease progression to date. 
We have no way of knowing the timing of viral clearance for participants who cleared the virus spontaneously 
prior to HCV testing (and thus had no positive RNA results). However, studies have found that spontaneous viral 
clearance usually occurs within a year of infection, so we assumed that these participants experienced acute 
infection only and were never chronically infected. 22,23
In order to facilitate the comparison of participants who developed chronic infection and those who cleared the 
virus spontaneously after acute infection with HCV and never developed chronic infection, most data are presented 
separately for participants who ever tested RNA positive and those who had RNA tests done but had no positive 
RNA results. The small number of participants who had no RNA results in their charts was omitted from most of 
the results presented by RNA status as they could not be classified as either “ever” or “never” testing RNA positive. 
Results for the ever RNA positive group are also presented separately for those who remain chronically infected 
(currently chronically infected) and those who were chronically infected in the past and have since cleared the virus 
(chronically infected in past), mostly as a result of anti-viral treatment.
Overall, 62% (n=815) of database participants had at least one positive RNA result in their charts (figure 4) and a 
further 15% (n=194) had positive confirmatory tests for HCV antibodies but no positive RNA results. The remaining 
23% (n=307) tested either ELISA/EIA positive or weak positive, or RIBA/INNO-LIA indeterminate, and had no other 
positive HCV results. People with positive or weak positive ELISA/EIA tests or indeterminate RIBA/INNO-LIA tests 
were included in the database as many patients were tested many years after suspected infection, having had 
documented exposure to HCV, and some of these may have cleared the virus and since sero-reverted. HCV antibody 
levels have been demonstrated to drop below detection limits in some patients.24,25,26
Twenty two percent (n=37) of participants infected through clotting factors had no RNA test results in their charts 
(figure 4). All were deceased and most had died in the early to mid 1990s. RNA tests were only commonly used from 
1994 onwards in Ireland. These participants were found to be similar to participants known to be chronically infected 
in terms of liver-related outcomes and it is likely that a large proportion would have been RNA positive if they had 
been tested prior to their death.  
Once participants with no RNA results were excluded, the overall spontaneous viral clearance rate, as determined 
by testing RNA negative at the time of first diagnosis, was 36%. This varied by gender and source of infection. 
Females (n=414, 41%) were significantly more likely to have cleared the virus by the time of their diagnosis than 
males (n=37, 14%). This gender imbalance remained but was significantly lessened when anti-D participants were 
excluded (23% for females compared to 14% for males). 
Some participants did not have positive confirmatory results for HCV. A proportion of these may have had 
false positive ELISA/EIA results, making the viral clearance rate appear higher than it actually was. When only 
participants with positive confirmatory results for HCV were analysed, 19% had cleared the virus spontaneously by 
the time they were diagnosed. Therefore the true spontaneous viral clearance rate is likely to be between 19% and 
36%.
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Figure 4. Hepatitis C RNA results for all participants and by source of infection. 
End of latest follow-up 
Data up to the end of 2009, where available, were collected for this round of data collection. However, latest follow-
up for each participant is effectively the last time they visited their hepatology unit, their last test result or their date 
of death, as this is the last date when information was recorded in their medical charts. 
Seventy six percent of all living database participants had attended their hepatology unit in 2008 or 2009 and a 
further 3% had been followed up through other services within the same hospital in this time period. The frequency 
of attendance at the hepatology units varied with RNA status. Eighty eight percent of participants who had ever 
been chronically infected attended their unit in 2008 or 2009 and a further four percent were followed up through 
other services in the hospital. Participants who had never become chronically infected were less likely to have 
attended recently, with 57% attending in 2008 or 2009 and an additional 4% attending other services in the 
hospital. Some database participants are likely to have moved abroad and may be lost to follow-up and some of the 
participants who never became chronically infected may have been discharged to the care of their GPs.
Database participants by source of infection
Participants infected through contaminated anti-D immunoglobulin
The anti-D group is entirely composed of females who were infected during their child-bearing years (median age 
at infection: 28 years) (figure 5, table 13). As a group, they would be expected to have been relatively healthy when 
infected. 
Infection due to contaminated anti-D has been largely traced to batches of anti-D from two infected donors.27 
Batches from the first donor were contaminated with genotype 1 HCV and were distributed between 1977 and 
1979. Eighty four percent (n=679) of anti-D participants were infected during this period. Batches from the second 
donor were infected with genotype 3 HCV. These were administered between 1991 and 1994 and accounted for nine 
percent (n=73) of participating anti-D participants. The genotype for five additional participants infected between 
1991 and 1994 did not match the outbreak genotype. The estimated year of infection for the remaining fifty one 
participants was outside of these outbreak periods and sixty seven percent of these (n=34) did not have positive 
confirmatory results for HCV. The source of their infection is unclear. 
By latest follow-up, the median age of anti-D participants who became chronically infected was 58 years and the 
median duration of RNA positivity was 32 years. Eighty percent had been RNA positive for 25 years or longer.
Participants infected through contaminated blood transfusions or treatment for renal disease
This group was the most heterogeneous in terms of age and gender (figure 5, table 13). They had the highest median 
age at infection (32), but this ranged from 0 to 77 years. Fifty six percent of chronically infected participants were 
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female and forty four percent were male, making this the only group with sizeable proportions of each gender. Using 
the assumptions outlined in chapter 3, most of the blood transfusion/renal participants were infected in the late 
1970s and 1980s. They had the shortest duration of RNA positivity at latest follow-up, with 34% positive for 25 years 
or longer. At latest follow-up, the median age of transfusion/renal participants who became chronically infected was 
61 years and the median duration of RNA positivity was 21 years.
Participants infected through contaminated blood clotting factors
Participants infected through clotting factors were predominantly male (93%) and 42% were co-infected with HIV 
(figure 5). Using the assumptions outlined in chapter 3, most were infected as children in the mid-1970s to early 
1980s. The median age at infection was 13 years for the group as a whole and 14 years for those who were chronically 
infected (table 13). By latest follow-up, the median age for clotting factor participants who became chronically 
infected was 42 years and the median duration of RNA positivity was 28 years (table 13). Seventy percent were RNA 
positive for 25 years or longer.
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Figure 5. Number of chronically infected participants by gender and source of infection (n=815). 
Note: The ‘All’ category includes 3 participants with “other” sources of infection.
The “Anti-D all” category includes participants infected in non-outbreak years and those with a non-outbreak genotype. 
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Table 13. Summary of age at infection, age at end of latest follow-up, years since infection and duration of RNA 
positivity by source of infection and RNA status.
Source of infection and RNA 
status
Age at infection
Age at end of follow 
up
Duration of infection 
(years since infection 
at last follow-up or 
death)
Duration RNA 
positivity 
  Median (range) Median (range) Median (range) Median (range)
Anti-D 28 (16-44) 57 (26-76) 32 (4-45)   
Ever chronically infected 28 (17-44) 58 (31-76) 32 (9-42) 32 (1-42)
Currently chronically infected 28 (17-44) 59 (33-76) 32 (9-42) 32 (9-42)
Chronically infected in past 28 (18-39) 55 (31-71) 31 (10-33) 18 (1-32)
Never chronically infected 28 (16-43) 57 (26-75) 31 (4-45)  
Anti-D 1977-1979 28 (17-44) 58 (33-76) 32 (17-33)  
Ever chronically infected 28 (17-44) 59 (33-76) 32 (17-33) 32 (15-33)
Currently chronically infected 28 (17-44) 60 (33-76) 32 (17-33) 32 (17-33)
Chronically infected in past 26.5 (18-39) 58.5 (47-71) 32 (27-33) 25 (15-32)
Never chronically infected 28 (17-43) 58 (41-75) 31 (17-33)  
Anti-D 1991-1994 30 (18-39) 46 (26-56) 16 (4-18)  
Ever chronically infected 30 (19-39) 46 (31-56) 16 (10-18) 6 (1-18)
Currently chronically infected 26 (23-30) 43 (34-48) 18 (11-18) 18 (11-18)
Chronically infected in past 30 (19-39) 46 (31-56) 16 (10-18) 5 (1-15)
Never chronically infected 31 (18-39) 45 (26-56) 14 (4-18)  
Transfusion or renal 32 (0-77) 61 (16-91) 23 (1-48)  
Ever chronically infected 32 (0-77) 61 (16-91) 24 (1-48) 21 (1-46)
Currently chronically infected 35 (0-77) 63 (19-61) 23 (1-46) 23 (1-46)
Chronically infected in past 27 (0-66) 53 (16-83) 25 (13-48) 18 (4-39)
Never chronically infected 34 (0-63) 60 (16-91) 22 (7-38)  
Clotting factors 13 (0-59) 42 (12-81)             27 (8-50)  
Ever chronically infected 14 (0-53) 44 (18-81) 31 (14-50) 28 (4-50)
Currently chronically infected 15 (0-53) 46 (18-81) 31 (14-50) 31 (14-50)
Chronically infected in past 12.5 (0-33) 43 (30-66) 32 (17-40) 25 (4-40)
Never chronically infected 12 (0-38) 39 (19-71) 28 (11-38)  
All 28 (0-77) 57 (12-91) 30 (1-50)  
Ever chronically infected 28 (0-77) 57 (16-91) 31 (1-50) 30 (1-50)
Currently chronically infected 28 (0-77) 59 (18-91) 32 (1-50) 32 (1-50)
Chronically infected in past 27 (0-66) 53 (16-83) 28 (10-48) 19 (1-40)
Never chronically infected 28 (0-63) 57 (15-91) 30 (4-45)  
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Genotype
The HCV genotype was available for nearly all of the database participants who became chronically infected (n=776, 
95%). Genotype 1 predominated: 76% (n=593) were infected with genotype 1, 18% (n=143) were infected with 
genotype 3, 5% (n=36) were infected with genotype 2 and four participants were infected with genotypes 4 or 5 
(figure 6). 
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Figure 6. Distribution of hepatitis C genotypes by source of infection (n=772, genotypes 4 & 5 omitted, n=4)
Alcohol consumption
At the time of this study, the low-risk drinking guidelines for the general population in Ireland defined an upper 
limit of 21 units (standard drinks) per week for males and 14 units per week for females. 28 (Note: Low-risk drinking 
guidelines have been revised and are now defined as 11 standard drinks for women and 17 standard drinks for men, 
per week.29)
Participants consuming between these limits (21 for males, 14 for females) and 40 units per week were classified as 
having moderately high alcohol intake and those consuming over 40 units were classified as having high alcohol 
intake. Some data on units of alcohol were available for 93% of those who became chronically infected. However, 
it is unusual for alcohol consumption to have been recorded at every visit, and in many cases it was last recorded 
many years ago. Alcoholic liver disease or alcohol abuse was also mentioned in the charts of some participants. 
This additional information was combined with alcohol intake data when looking at the effects of alcohol on disease 
progression and these participants were considered to have had high alcohol intake at some stage. Alcohol intake in 
excess of the recommended limits was recorded in the medical charts of 15% of chronically infected participants for 
whom data were available (table 14). 
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Table 14. Highest recorded alcohol intake for all database participants and by RNA status (where data 
available, n=1193, 93%)*
Alcohol consumption All
Ever 
chronically 
infected
Currently 
chronically infected
Chronically 
infected in past
Never chronically 
infected
  Num % Num % Num % Num % Num %
Non drinker 296 24.8 183 24 143 25.4 40 20.1 107 25.9
Within recommended 
limits
739 61.9 461 60.6 329 58.5 132 66.3 270 65.4
Moderately high 76 6.4 54 7.1 37 6.6 17 8.5 21 5.1
High 82 6.9 63 8.3 53 9.4 10 5 15 3.6
Total 1193   761   562   199   413  
* No alcohol intake data for 123 database participants. RNA status not known for 19 participants with alcohol intake data. Data for these 
participants shown under the “All” category, but not by RNA status
Differences in alcohol consumption by gender and source of infection
Males and females differed in their reported exposure to alcohol with 32% (n=62) of chronically infected males 
exceeding the recommended limits for alcohol intake compared to 10% (n=55) of females (figure 7). Younger 
participants were also more likely to drink alcohol in excess of recommendations. Alcohol consumption differed by 
source of infection with participants infected through anti-D significantly less likely to consume alcohol in excess of 
recommendations compared to those infected through other means (figure 8). However, this is likely to be largely 
attributable to the differences in age and gender by source of infection. 
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Figure 7. Distribution of highest reported alcohol consumption by gender for participants who became 
chronically infected (where data available, n=761, 93%)
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Figure 8. Distribution of highest reported alcohol consumption by source of infection for participants who 
became chronically infected (where data available, n=761, 93%).
 
Outcomes
Clinical signs of liver disease
One hundred and eighty seven (14.2%) participants had one or more clinical signs of liver disease recorded in their 
charts at latest follow-up. Eighty percent of these (n=149) were currently chronically infected, 14% (n=26) were 
chronically infected in the past, 4% (n=7) had no RNA results in their charts and 3% (n=5) never tested RNA positive. 
The most common conditions or signs recorded were cirrhosis, varices, portal hypertension and ascites. (See table 
15 for a list of clinical signs included).
Table 15. Number and percentage of participants with clinical signs of liver disease by RNA status*
Clinical signs of liver disease All Ever chronically infected
Currently 
chronically 
infected
Chronically 
infected in past
Never 
chronically 
infected
  Num % Num % Num % Num % Num %
Cirrhosis 142 10.8 137 16.8 118 19.5 19 9.1 0 0.0
Varices 68 5.2 66 8.1 60 9.9 6 2.9 0 0.0
Portal hypertension 58 4.4 57 7.0 49 8.1 8 3.8 0 0.0
Ascites 57 4.3 53 6.5 50 8.3 3 1.4 3 0.7
Hepatomegaly or 
splenomegaly or both 65 4.9 61 7.5 53 8.8 8 3.8 4 0.9
HCC 34 2.6 32 3.9 31 5.1 1 0.5 0 0.0
Encephalopathy 25 1.9 23 2.8 22 3.6 1 0.5 1 0.2
Decompensated liver disease 12 0.9 11 1.3 10 1.7 1 0.5 0 0.0
Hypersplenism 4 0.3 4 0.5 3 0.5 1 0.5 0 0.0
Hepatorenal syndrome 1 0.1 1 0.1 1 0.2 0 0.0 0 0.0
Portal gastropathy 1 0.1 1 0.1 1 0.2 0 0.0 0 0.0
Hepatosynthethic dysfunction 1 0.1 1 0.1 1 0.2 0 0.0 0 0.0
Hepatopulmonary syndrome 1 0.1 1 0.1 1 0.2 0 0.0 0 0.0
One or more signs of liver 
disease 187 14.2 175 21.5 149 24.6 26 12.4 5 1.1
*7 participants with one or more signs of liver disease (including 5 with cirrhosis) had no RNA results in their charts
Cirrhosis
By latest follow-up, 17% (n=137) of ever chronically infected participants had developed cirrhosis (table 15). Eighty 
six were female (15% of ever RNA positive females) and fifty one were male (23% of ever RNA positive males) (table 
16). Five deceased participants with no RNA results in their charts had also developed cirrhosis. For ever chronically 
infected database participants, the median duration of RNA positivity at the estimated date of cirrhosis (see chapter 
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3 re methods used) was 24 years and the median age at cirrhosis was 53 years. There were no cases of cirrhosis in 
those who never developed chronic HCV infection. 
The number of participants with cirrhosis has increased by 26 since the last round of data collection. Sixteen were 
diagnosed with cirrhosis in 2009, four were new database participants who had died, all of whom were diagnosed 
with cirrhosis in 2008, and the remaining six had previous comments relating to potential cirrhosis which were since 
clarified.
Note: A diagnosis of cirrhosis was assigned if cirrhosis was mentioned in the patient’s medical chart (whether ever diagnosed by biopsy, ultrasound 
scan, CT scan etc) or on death certificate. Based on biopsy results alone, 86 of 679 chronically infected participants (13%) ever had a diagnosis of 
cirrhosis.
After RNA status, alcohol consumption was the biggest determinant of risk of cirrhosis in the database cohort. 
Where alcohol data were recorded, 23% of ever chronically infected participants with cirrhosis had consumed over 
40 units of alcohol per week or had alcohol abuse or alcoholic liver disease recorded in their charts at some stage 
compared to 5% of ever chronically infected participants without cirrhosis. Factors independently associated with 
cirrhosis were: current chronic infection compared to past chronic infection (or longer duration of infection) (figure 
9), male gender, high alcohol intake and genotype 3 infection. The prevalence of cirrhosis also varied by source of 
infection, with participants infected through transfusions or treatment for renal disease significantly more likely to 
have developed cirrhosis compared to those infected through anti-D (table 16).
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Figure 9. Comparison of rates of cirrhosis for participants who are currently chronically infected, were 
chronically infected in the past and have since cleared the virus, and those who were never chronically infected.
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Table 16. Summary of cirrhosis by gender and source of infection for ever chronically infected participants
Source of infection
Number 
with 
cirrhosis
% with 
cirrhosis
% of those with cirrhosis 
with high alcohol 
consumption
Median age at 
cirrhosis in years 
(range)
Median duration 
RNA positivity at 
cirrhosis in years 
(range)
Gender          
Females 86 14.5 19.8 55 (24-81) 24 (6-46)
Males 51 23.2 29.8 51 (23-79) 22 (5-38)
Source of infection          
Anti-D 49 11.3 18.4 52 (38-70) 24 (7-33)
Transfusion or renal 70 25.6 21.4 55.5 (23-81) 20.5 (1-46)
Clotting factors 17 15.9 29.4 45 (31-61) 27 (13-38)
Hepatocellular carcinoma (HCC)/liver cancer
By latest follow-up, 32 (4%) ever chronically infected participants and two participants with no RNA results had 
developed HCC or liver cancer (figure 10). This is an additional nine participants compared to the previous round 
of follow-up data collection. All were diagnosed with HCC in 2009. There were no cases of HCC in those who never 
developed chronic infection.
The prevalence of HCC was significantly higher in chronically infected males (n=20, 9%) compared to chronically 
infected females (n=12, 2%). Chronically infected participants infected through blood transfusions/treatment for renal 
disease and those infected through contaminated clotting factors were also significantly more likely to have developed 
HCC compared to those infected through contaminated anti-D (table 17). Where alcohol data were available, eight 
(28%) of those with HCC had high alcohol intake at some stage.
Twenty seven (79%) of the participants with HCC were known to be deceased. The cause of death was directly 
liver-related for twenty two, not liver-related for three and the death certificate was missing for the remaining two 
participants. The median duration of infection at the time of HCC diagnosis was 27.5 years (range: 5-40 years) and the 
median age at diagnosis of HCC was 63 years (range: 43-82 years). (See chapter 3 re methods used).
The median time from estimated date of diagnosis of cirrhosis to estimated date of diagnosis of HCC was three years. 
Cirrhosis was not specifically mentioned in the charts or on the death certificates of five of the participants with HCC. 
However, two of these participants had ascites and one had varices. See section on liver transplants below.
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Figure 10. Comparison of rates of HCC for participants who are currently chronically infected, were chronically 
infected in the past and have since cleared the virus, and those who were never chronically infected.
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Table 17. Summary of HCC by gender and source of infection for ever chronically infected participants.
Gender and source of 
infection
Number with HCC % with HCC
Median age at HCC 
in years (range)
Median duration 
RNA positivity at 
HCC in years (range)
Gender        
Females 12 2.0 67 (47-74) 29.5 (21-40)
Males 20 9.1 61.5 (43-82) 24 (5-38)
Source of infection        
Anti-D 5 1.2 66 (47-68) 30 (27-32)
Transfusion or renal 21 7.7 70 (44-82) 25 (5-40)
Clotting factors 6 5.6 54.5 (43-63) 28.5 (22-38)
Liver biopsy results
Most of the liver biopsies were carried out in the mid to late 1990s, with much smaller numbers being done in more 
recent years (figure 11). Thirty seven participants had a biopsy in 2008 and thirty four had a biopsy in 2009. Overall, 
the likelihood of having a biopsy varied by RNA status with 83% (n=679) of chronically infected participants having a 
biopsy compared to 24% (n=110) of those with no positive RNA results. Participants infected through contaminated 
clotting factors were least likely to have had biopsies, with only 37% (n=40) of those ever testing RNA positive 
having biopsy results in their charts compared to 96% (n=415) of chronically infected anti-D participants and 81% 
(n=222) of those infected through blood transfusions or treatment for renal disease. Disease progression may be 
more likely to be monitored using ultrasounds, CT scans and other tests for participants infected through clotting 
factors and the available biopsy results in these participants are not likely to be a good indicator of disease status or 
progression. 
Figure 11. Number of biopsies done by year of biopsy and RNA status of participant
Inflammation
Of the 1,679 liver biopsies carried out, inflammation grade was available for 99%. Twenty six percent (n=178) of 
ever chronically infected participants had moderate or severe inflammation on last biopsy compared to 1% (n=1) of 
participants who did not become chronically infected. Inflammation grade on biopsy varied by source of infection 
with 34% of chronically infected transfusion/renal participants having moderate or severe inflammation on their last 
biopsy compared to 23% of anti-D participants and 23% of participants infected through clotting factors. 
Fibrosis
Of the 1,679 liver biopsies carried out, fibrosis scores were available for 91%. Fibrosis was scored using different 
scoring systems in different hepatology units. Overall 78% of biopsies were scored using a 0-6 scoring system, and 
a 0-4 system was used for the remaining 22%. Biopsy results scored from 0 to 6 were converted to the 0 to 4 scores 
(see chapter 3 for details) for some analyses to allow all biopsy results to be analysed together. 
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We considered high fibrosis scores to be scores of 4-6 on biopsies scored from 0-6 and scores of 3-4 on biopsies 
scored from 0-4. Nineteen percent (n=127) of chronically infected participants had a high fibrosis score on their most 
recent biopsy (where fibrosis score was recorded, n=653) compared to 4% (n=4) of those who never tested RNA 
positive (where fibrosis score was recorded, n=104). Fibrosis also varied by source of infection. Thirty two percent 
(n=66) of chronically infected blood transfusion or renal participants had a high fibrosis score on most recent biopsy 
compared to 23% (n=9) of clotting factor participants and 13% (n=52) of anti-D participants (figure 12).  
Aside from chronic infection, risk factors independently associated with ever having a high fibrosis score on biopsy 
were: male gender, older age at last biopsy (55+ compared to less than 55 years), genotype 3 infection (compared to 
genotype 1 infection) and ever having high levels of alcohol consumption. 
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Figure 12. Fibrosis score* on last biopsy for chronically infected participants by source of infection (n=653).
* All 0-6 scores standardised to 0-4 (see chapter 3 for description) to allow all biopsies to be analysed together. 
Note: results for clotting factor participants are not representative as data are only available for 39 and the last biopsy was several years ago for 
many patients.
Changes in biopsy results post treatment
Eighty seven chronically infected participants who had pre-treatment biopsy results also had biopsy results at least 
six months after treatment. The changes in fibrosis scores (all standardised to 0 to 4 system) by anti-viral treatment 
response are shown in figure 13. Fibrosis scores improved for 57% (n=12) of those who achieved sustained virological 
response (SVR) on treatment compared to 35% (n=23) of those who did not. 
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Figure 13. Changes in fibrosis scores (0-4) after treatment, by SVR status for participants who had pre- and 
post-treatment biopsy results (n=87).
* All 0-6 scores standardised to 0-4 (see chapter 3 for description) to allow all biopsies to be analysed together. Numbers in some categories are 
very low and percentages should be interpreted with caution.
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Liver function tests – alanine aminotransferase (ALT)
Ninety five percent of database participants had at least one ALT result in their charts and 71% had two or more 
tests done. Levels were elevated on at least one test for 74% of currently chronically infected participants, 33% of 
participants who were chronically infected in the past and have since cleared the virus and 14% of those with no 
positive RNA results. Twenty five percent of currently chronically infected participants had ALT levels 2.5 or more 
times the upper normal limit on at least one test compared to 9% of those who were chronically infected in the past 
and 2% of those who never became chronically infected.
 
In addition to chronic infection, the independent risk factors for ever having elevated ALT levels, and for having ALT 
levels 2.5 or more times the upper normal limit on any test, were current chronic infection (compared to past chronic 
infection) and male gender. Participants infected through clotting factors had the highest ALT levels but this may 
be due to high proportion of males in this group. Table 18 shows the highest ALT results by RNA status, gender and 
source of infection. 
Table 18. Highest alanine amino transferase results by RNA status, gender and source of infection
Alanine aminotransferase 
results
Ever chronically 
infected (%)
Currently 
chronically infected 
(%)
Chronically infected 
in past (%)
Never chronically 
infected (%)
Females        
Normal 39.6 29.1 71.7 87.4
Elevated: <2.5 times upper 
normal limit 41.1 47.5 21.4 10.4
Elevated: >2.5 times upper 
normal limit 19.3 23.3 6.9 2.2
Males        
Normal 28.9 18.1 55 73.5
Elevated: <2.5 times upper 
normal limit 45.1 50.7 31.7 23.5
Elevated: >2.5 times upper 
normal limit 26 31.3 13.3 2.9
Anti-D        
Normal 35.2 25.1 70.5 86.9
Elevated: <2.5 times upper 
normal limit 45.5 52.4 21.1 10.6
Elevated: >2.5 times upper 
normal limit 19.3 22.5 8.4 2.5
Transfusion or renal        
Normal 42.5 33.2 64.6 86.4
Elevated: <2.5 times upper 
normal limit 35.7 39.6 26.6 11.9
Elevated: >2.5 times upper 
normal limit 21.8 27.3 8.9 1.7
Clotting factors        
Normal 27.8 12.1 61.3 73.7
Elevated: <2.5 times upper 
normal limit 45.4 53 29 26.3
Elevated: >2.5 times upper 
normal limit 26.8 34.8 9.7 0
Deceased participants
Two hundred and twelve participants had died by latest follow-up. This represents twenty five additional deceased 
participants compared to the previous round of follow-up data collection. Seventeen died in 2009, three died in 
2008, three died in earlier years but were newly identified as deceased, and date of death was not available for the 
remaining two. All cause mortality rates varied significantly by RNA status: 23% of currently chronically infected 
participants were deceased by latest follow-up compared to 4% of participants who were chronically infected in 
the past and had since cleared the virus (mostly through treatment) and 6% of participants who never became 
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chronically infected (figure 14). All cause mortality was also significantly higher in males or participants infected 
through blood transfusions or clotting factors and those who had high alcohol intake.
Figure 14. Comparison of liver-related mortality rates for participants who are currently chronically infected, 
were chronically infected in the past and have since cleared the virus, and those who were never chronically 
infected.
Where death certificates were available (n=199), death was directly caused by liver disease for 55 participants. The 
causes of death for these 55 were:
•   liver cell carcinoma (n=20)
•   cirrhosis of the liver (n=15) 
•   liver failure (n=10) (one caused by hepatitis B) 
•   chronic viral hepatitis C (n=4)
•   hepatorenal failure (n=2)
•   oesophageal varices (n=2)
•   toxoplasma hepatitis (n=1)
•   hepatic encephalopathy (n=1). 
HCV infection was one of the causes of death listed on the first part of the death certificate for forty one of the 
participants who died from liver-related causes. The first part of the death certificate details the chain of diseases or 
conditions leading directly to death. 
Liver-related mortality was significantly higher in participants who were currently chronically infected with HCV 
(n=43, 7.2%) and those with no RNA results in their charts (n=8, 17.4%) compared to those who never became 
chronically infected (n=2, 0.4%) and those who had been chronically infected in the past and had since cleared the 
virus (mostly through treatment) (n=2, 1%) (figure 15).
High alcohol intake was a highly significant predictor of liver-related mortality. Information on alcohol consumption 
was available for 82% of those whose death was caused by liver disease. Forty four percent had indicators of high 
levels of alcohol consumption in their medical charts. Liver-related mortality rates were also higher in males and in 
those infected through blood transfusions or clotting factors. 
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Figure 15. Comparison of liver-related mortality rates for participants who are currently chronically infected, 
were chronically infected in the past and have since cleared the virus, and those who were never chronically 
infected.
Table 19. Number and percentage of ever chronically infected participants who died directly from liver-related 
disease, by gender and source of infection
Gender and source of 
infection
Number who died 
directly from liver-
related disease
% who died directly 
from liver-related 
disease
Median age at death
Median duration 
RNA positivity at 
death in years (range)
Gender        
Females 24 4.1 62.5 (37-74) 27 (11-41)
Males 21 9.8 54 (39-82) 22 (8-38)
Source of infection*        
Anti-D 11 2.6 54 (44-69) 30 (19-32)
Transfusion or renal 21 7.8 71 (43-82) 21 (8-41)
Clotting factors 12 11.3 47.5 (37-58) 26 (16-38)
*Information relating to source of infection was missing on one participant who died directly from liver-related disease
Changes in the prevalence of the main liver-related outcomes since baseline data were 
collected
HCV disease progresses particularly after two to four decades of infection.6 The median time since infection for the 
database population is now 30 years and the median duration of RNA positivity for those who became chronically 
infected is also 30 years (currently RNA positive: 32 years, RNA positive in past: 19 years). This is the fourth round 
of data collection and increases can be seen in the prevalence of liver-related health outcomes since baseline data 
were collected (figure 16).
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Figure 16. Changes in the prevalence of all cause mortality and liver-related outcomes for chronically infected 
participants since baseline data were collected.  
Note: Percentages at baseline may differ slightly from baseline report due to slight changes in the way results are coded or analysed or where 
data are extracted from. The denominators may also have changed slightly due to the identification of several ineligible patients or duplicates.
Summary of disease progression and factors associated with disease severity
As there were several outcome measures that could be used to indicate HCV disease severity, a variable was created 
to summarise disease progression. 
A participant was considered to have ‘severe liver disease’ if they had:
•   Died from liver-related disease or
•   Had ever had one or more of the following signs of liver disease: cirrhosis, primary liver cancer, ascites, varices, 
decompensated liver disease, portal hypertension, encephalopathy, hepatomegaly or splenomegaly or
•   Had ever had a fibrosis score of 3 or 4 on a biopsy scored from 0 to 4 or a score between 4 and 6 on a biopsy 
scored from 0 to 6 (note: this is “worst” biopsy result, not necessarily most recent one; some patients may have 
improved on treatment)
A participant was considered to have ‘moderate liver disease’ if they had none of the above and 
had either:
•   A fibrosis score of 2 on a biopsy scored from 0 to 4 or a score of 3 on a biopsy scored from 0 to 6 or
•   Moderate or severe inflammation on any biopsy
All other participants were classified as having ‘mild or no liver disease’. 
Using these criteria, 31% (n=190) of currently chronically infected participants, 20% (n=43) of participants who were 
chronically infected in the past, 22% (n=11) of those with no RNA results and 2% (n=7) of those who were never 
chronically infected were classified as having severe liver disease by latest follow-up.
 
Tables 20 and 21 show the effects of some key host and virus characteristics on the odds of having severe liver 
disease. Only participants who tested RNA positive at some stage (ever chronically infected) were included in these 
analyses as 93% of the participants with severe disease had tested RNA positive at some stage and this approach 
allowed the effects of genotype to be assessed. 
The determinants of having severe liver disease in the database cohort were high alcohol intake, older age at 
end of latest follow-up, male gender, longer duration of RNA positivity and HCV genotype 3 (table 20). Table 21 
shows the same model with source of infection substituted for gender. These factors cannot be assessed together 
using a logistic regression model as gender is too closely linked to source of infection in the database population. 
This model indicates that participants infected through blood transfusions/treatment for renal disease and those 
- 38 -
National Hepatitis C Database for infection acquired through blood and blood products HPSC
infected through clotting factors were more likely to have severe liver disease by latest follow-up compared to those 
infected through anti-D. All associations between these characteristics and severe liver disease were statistically 
significant and the influence of each of these factors on disease severity was independent of the effects of all of the 
other factors in the table. 
The most important factor in disease progression was alcohol intake. Participants who had high alcohol intake had 
more than five times higher odds of having severe disease compared to those without. However, the number of 
chronically infected database participants with high alcohol intake was low (n=63, 8.3%) and due to its sensitivity, 
alcohol consumption data may be inaccurately reported. Figures 17 and 18 show the prevalence of severe liver 
disease by duration of RNA positivity, alcohol intake, gender and source of infection.
Participants who were RNA positive for more than twenty years had approximately two fold higher odds of having 
severe liver disease compared to those infected for less than twenty years. The odds of having severe liver disease 
were almost three times higher for males compared to females. Participants who were aged 50 years or older at 
latest follow-up were more likely to have severe liver disease than younger participants. 
Table 20. Factors associated with severe liver disease in chronically infected participants - logistic regression 
model including gender (n=727). 
Factors associated with having severe 
liver disease
Odds Ratio P-value 95% Confidence interval
Alcohol consumption      
Non drinker/within recommended limits/
moderately high 1 Reference Reference
High (>40 units per week or alcohol 
abuse in chart) 5.6 <0.001 3.02 - 10.52
Age at end of latest follow-up      
<50 years 1 Reference Reference
50 to 64 years 2.7 <0.001 1.60 - 4.55
65+ years 3.7 <0.001 2.11 - 6.53
Gender      
Female 1 Reference Reference
Male 2.8 <0.001 1.83 - 4.37
Genotype      
Genotype 1 1 Reference Reference
Genotype 2 0.9 0.762 0.35 - 2.14
Genotype 3 2.2 0.002 1.32 - 3.61
Duration of RNA positivity      
<20 years 1 Reference Reference
20+ years 2.2 0.002 1.32 - 3.58
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Table 21. Factors associated with severe liver disease in chronically infected participants - logistic regression 
model including source of infection (n=725). 
Factors associated with having severe 
liver disease
Odds Ratio P-value 95% Confidence interval
Alcohol consumption      
Non drinker/within recommended lim-
its/moderately high
1 Reference Reference
High (>40 units per week or alcohol 
abuse in chart)
5.5 <0.001 2.97 - 10.36
Age at end of latest follow-up      
<50 years 1 Reference Reference
50 to 64 years 2.2 0.003 1.31 - 3.66
65+ years 2.6 0.001 1.47 - 4.55
Source of infection      
Anti-D 1 Reference Reference
Transfusion or renal 2.8 <0.001 1.85 - 4.35
Clotting factors 2.1 0.025 1.09 - 3.93
Genotype      
Genotype 1 1 Reference Reference
Genotype 2 0.6 0.286 0.25 - 1.51
Genotype 3 1.9 0.016 1.12 - 3.10
Duration of RNA positivity      
<20 years 1 Reference Reference
20+ years 2.4 0.001 1.47 - 4.02
Explanatory note: The odds ratios shown are a measure of the odds of severe liver disease in one group (e.g. males) divided by the odds of severe 
disease in another group (the reference group e.g. females). An odds ratio of 1 indicates that severe liver disease is equally likely in both males and 
females and an odds ratio of more than 1 for males indicates that severe disease is more likely in males. P-values of <0.05 were taken to indicate a 
statistically significant difference between the distribution of severe disease in the category of the factor being assessed and the reference category of 
that factor.
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Figure 17. Percentage of chronically infected participants with severe liver disease by gender, duration of RNA 
positivity and alcohol consumption 
Note: Numbers in some categories are very low and percentages should be interpreted with caution
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Figure 18. Percentage of chronically infected participants with severe liver disease by source of infection, 
duration of RNA positivity and alcohol consumption 
Note: Numbers in some categories are very low and percentages should be interpreted with caution
Anti-viral treatment for hepatitis C
Forty two percent (n=344) of chronically infected participants had one or more courses of anti-viral treatment by 
latest follow-up. Participants stopping treatment early are included when calculating sustained virological response 
(SVR). The SVR rate has improved in recent years with the advent of combination therapy with pegylated interferon 
(peg-IFN) and ribavirin (RBN) (figure 19). Tolerance of anti-viral treatment remains an issue, with 24% (n=104) of 
all treatment courses stopped early due to side-effects. The percentage stopping treatment early was lower for 
combination therapy with peg-IFN and RBN (17%, n=32) than for combination therapy with IFN and RBN (28%, 
n=24) or monotherapy with IFN or peg-IFN or RBN (28%, n=48).
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Figure 19. Treatment courses by type of treatment and percentage sustained virological response, 1992-2009 
Note: Outcome is awaited for 13 participants who were treated in 2009 and 4 participants who were treated in 2008. These are not included 
when calculating SVR
Younger participants, those infected in the 1991-1994 anti-D outbreak, or through blood transfusions or clotting 
factors, those with higher fibrosis scores and participants with genotype 2 or 3 infections were more likely to have 
been treated (table 22). However, of the 52 participants who commenced treatment between 2007 and 2009, 43 
(83%) were genotype 1. This was the first course of treatment for 36 (69%), second for 14 (27%) and third for 2 (4%) 
participants. A high fibrosis score was recorded for 10 (19%) of these recently treated participants.
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Treatment response  
Seventy three percent of genotype 2 or 3 treatment naïve participants on peg-IFN and RBN combination therapy 
achieved an SVR compared to 41% of genotype 1 participants on the same treatment (table 22). Treatment response 
for treatment naïve participants on peg-IFN and RBN, by genotype and type and duration of treatment, are shown in 
figure 20.
Table 22. Number and percentage of chronically infected participants treated, and percentage SVR, by source 
of infection, gender, fibrosis scores, hepatitis C genotype and age at latest follow-up
Characteristic
Number of 
participants 
treated - any 
drug regimen
% treated - any 
drug regimen
% SVR on first 
treatment - any 
drug regimen
% SVR on first 
treatment with 
Peg-IFN & RBN - 
treatment naive 
participants
% SVR on first 
re-treatment 
with Peg-IFN & 
RBN - previously 
failed tx on other 
drugs 
Source of infection          
Anti-D all* 151 35.0 35.9 44.2 28.6
Anti-D 77-79 109 28.8 23.8 44.2 16.7
Anti-D 91-94 33 86.8 75.8 57.1 100.0
Blood clotting factors 54 50.5 34.6 54.2 27.3
Blood transfusion/renal 139 50.9 38.2 57.1 36.4
Gender          
Female 236 39.7 36.9 45.1 27.3
Male 108 49.1 36.2 62.8 38.1
Ever had a high fibrosis score 
on biopsy          
No 201 40.7 44.1 48.6 40.7
Yes 99 61.9 19.4 45.2 15.0
Genotype          
1 208 35.1 23.6 41.0 18.9
2 25 69.4 44 72.7 75.0
3 99 69.2 57.6 73.3 53.8
Age at latest follow up          
0 to 49 years 111 55.5 50.9 70.7 47.1
50 to 59 years 128 46.7 35.5 51.1 23.8
60+ years 105 30.8 22.8 30.8 25.0
All 344 42.2 36.7 51.2 31.5
*Includes participants infected through anti-D in non-outbreak years. 
Genotype not available for 10 participants who were treated. Participants with genotypes 4/5 (n=4) omitted from analysis of treatment data. 
Fibrosis scores not available for 34 of the participants who were treated. Treatment outcome for the first course of treatment awaited for 14 
participants  – these participants were not included when calculating SVR. 
- 42 -
National Hepatitis C Database for infection acquired through blood and blood products HPSC
57.1
50
68.2
80
75
10
20
30
40
50
60
70
80
90
%
 S
VR
0
<24 weeks      
Treated =19
24-47 weeks     
Treated =28
48+ weeks      
Treated =36
<24 weeks      
Treated = 22
24-47 weeks     
Treated =15
48+ weeks     
Treated =4
Genotype 1 Genotypes 2 or 3
%
 S
VR
Genotype and duration of treatment
Figure 20. Percentage sustained virological response for treatment-naïve participants treated with combination 
therapy with Peg-IFN and RBN (n=124), by genotype and duration of therapy
The factors associated with SVR on first treatment were: treatment with combination therapy with peg-IFN and 
RBN rather than combination therapy with IFN & RBN or monotherapy, having HCV genotypes 2 or 3 rather than 
genotype 1, longer duration of treatment and lower fibrosis scores on biopsy. 
Treatment response: previously treated participants
Fifty four participants were re-treated with peg-IFN and RBN having failed to achieve SVR on previous treatment 
courses with other drug regimens. Their overall treatment response rate was 31.5%. However, response rates were 
good for genotype 1 participants who were treated for 48 or more weeks (50%) and for genotype 2 or 3 participants 
who were treated for 24 or more weeks (67%). Response rates by genotype and duration of treatment are shown in 
figure 21. 
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Figure 21. Percentage sustained virological response for re-treated participants (previously failed to achieve 
SVR on other drug regimens) treated with combination therapy with Peg-IFN and RBN (n=54), by genotype and 
duration of therapy
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Liver transplants 
Nineteen database participants had received twenty one liver transplants by the end of 2009. Fifteen received 
transplants in 2007 or earlier, three were transplanted in 2008 and one was transplanted in 2009. The median 
age at transplant was 53 years (range: 29-66 years) and the median duration of HCV infection at transplant was 
29 years (range: 1-39 years). All transplant recipients were RNA positive when transplanted and all of those tested 
post-transplant (n=16) remained RNA positive. Five transplant recipients (26%) had evidence of high alcohol 
consumption at some stage.
Fourteen transplant recipients had a diagnosis of cirrhosis before their liver transplant and one had HCC. Post-
transplant biopsy or other staging results were available for ten participants. Within five years of transplant, two 
developed HCC, two developed cirrhosis, two had moderate or advanced fibrosis, two had mild fibrosis and one had 
no fibrosis. One further participant developed cirrhosis many years after transplant.
Five of the liver transplant patients have since died. Three died from non-liver related causes, one from 
hepatocellular carcinoma and no death certificate was available for the fifth. The median time between transplant 
and death for these patients was 21 months.
Medical conditions 
Medical conditions recorded in participants’ medical charts were entered into the database.  However, these 
conditions may not have always been diagnosed according to standardised criteria and may not be related to HCV 
infection. Some medical conditions may also be underestimated if patients are treated privately and the condition is 
not discussed with the consultant hepatologist. However, if the condition was serious or known to be associated with 
HCV infection it is more likely to have been reported and recorded. 
Without a comparison group, it is not possible to determine if the prevalence of these conditions and procedures 
differed from the general population. However, if the condition was strongly associated with HCV infection, we 
would expect to see a significant difference in the prevalence of the condition between participants who became 
chronically infected and those who cleared the virus after acute infection. We excluded medical conditions that were 
known to pre-date HCV infection, but the year the condition was diagnosed was not always known.  
Table 23 shows common medical conditions and other medical conditions of interest, recorded by RNA status, and 
indicates conditions where there is a statistically significant (p<0.05) difference in the prevalence of the condition 
between participants who were ever chronically infected and those who were not. Differences should be interpreted 
with caution as follow-up was better for chronically infected participants and this may have led to a bias in the 
reporting and recording of medical conditions.
Depression was significantly more likely to be recorded in the medical charts of chronically infected participants 
(n=271, 33%) compared to those who never became chronically infected (n=95, 21%). Females were more likely to 
report depression than males after accounting for the effects of RNA status. Participants who had received anti-viral 
treatment were also more likely to have depression recorded in their medical charts. Long-term medications for 
depression, sleep disorders or anxiety were noted in the charts of 68% (n=183) of chronically infected participants 
with depression. 
Fibromyalgia was significantly more prevalent in chronically infected females compared to females who did not 
become chronically infected. Age also had an impact and females aged 50 years or older were more likely to have 
fibromyalgia than younger females.
Osteoporosis was significantly more likely to be recorded for females, participants who were older at most recent 
follow-up and those who became chronically infected
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Table 23. Medical conditions recorded in charts of participants – most common conditions, conditions that 
differed significantly by RNA status and other conditions of interest* excluding conditions known to pre-date 
hepatitis infection.
Disease or condition Chronically infected Never chronically 
infected
Statistically 
significant 
difference†
Statistically 
significant 
difference in 
females†
Statistically 
significant 
difference in 
males†
  Num % Num %      
Depression 271 33.3 95 21.1 Yes Yes No
Fatigue and lethargy 262 32.1 133 29.5 No Yes No
Arthralgia or joint pain 194 23.8 115 25.5 No No No
Hysterectomy ‡ 118 19.8 68 16.4   No  
Fibromyalgia 103 12.6 42 9.3 No Yes No
Osteoarthritis 91 11.2 44 9.8 No No No
Osteopenia 77 9.4 36 8 No No No
Dermatitis and eczema 70 8.6 21 4.7 Yes No Yes
Diabetes mellitus 68 8.3 20 4.4 Yes No No
Osteoporosis 60 7.4 11 2.4 Yes Yes No
Dry eyes/conjunctivitis 56 6.9 23 5.1 No No No
Anxiety 45 5.5 14 3.1 No Yes No
Arthritis, unspecified 31 3.8 14 3.1 No No No
Sicca/Sjorgen syndrome 22 2.7 8 1.8 No No No
Thrombocytopenia or other pur-
pura 17 2.1 2 0.4 Yes No No
Rheumatoid Arthritis 14 1.7 6 1.3 No No No cases
Parkinson’s Disease 6 0.7 2 0.4 No No No
Ovarian Cancer ‡ 5 0.8 0 0   No  
Brain tumour 4 0.5 0 0 No No No cases
Non-Hodgkin’s Lymphoma 4 0.5 0 0 No No No
* Data for some conditions, mentioned in literature as associated with HCV, or raised by patient groups, are included even if the condition was not 
commonly reported and no statistically significant difference was seen between ever and never chronically infected participants. 
†P <0.05
‡Percentage calculated using female denominator figures.
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Focus on the different patient groups
Database participants who became chronically infected with HCV through blood transfusions or treatment for renal 
disease had the highest prevalence of severe liver disease in spite of having the shortest median duration of RNA 
positivity at the end of latest follow-up. Thirty nine percent (n=107) of transfusion/renal participants were classified 
as having severe liver disease, including 26% (n=70) with cirrhosis, after a median duration of HCV RNA positivity by 
latest follow-up of 21 years. The prevalence of severe liver disease was also high in participants who were chronically 
infected through clotting factors, with 32% (n=34) classified as having severe liver disease and 16% (n=17) diagnosed 
with cirrhosis after a median duration of RNA positivity of 28 years. Chronically infected anti-D participants had 
better liver-related outcomes overall, with 21% (n=91) classified as having developed severe liver disease, including 
11% (n=49) with cirrhosis, after a median duration of RNA positivity of 32 years.
There are several potential explanations for these differences in liver-related outcomes. Firstly, we would expect 
co-morbidities to be high in transfusion/renal participants in general, as many were infected with HCV as a result 
of treatment for serious medical conditions such as cancer. Transfusion/renal participants were also slightly 
older overall when infected with HCV, with a median age at infection of 32 years, compared to 28 years for 
anti-D participants and 14 years for participants infected through clotting factors. Gender may also be a factor 
as chronically infected female participants have a lower prevalence of serious liver-related outcomes than males 
in spite of having longer durations of RNA positivity. Alcohol intake also varies by gender and hence by source of 
infection, with 12% of chronically infected transfusion/renal participants and 17% of chronically infected clotting 
factor participants consuming high levels of alcohol at some stage, compared to 4% of anti-D participants.
Participants infected through anti-D
In spite of having the longest median duration of RNA positivity, database participants infected through anti-D have 
the lowest prevalence of serious liver-related outcomes. This is likely to be attributable, in part, to the fact that this 
group was entirely composed of females who were infected during or after pregnancy and who were likely to have 
been in relatively good health when infected with HCV. Reported alcohol consumption was also lower for female 
database participants. Their median age at infection was 28 years, which makes them younger overall compared to 
the transfusion/renal group but significantly older than those infected through clotting factors. 
Anti-D participants infected between 1977 and 1979 have had the lowest uptake of antiviral treatment to date 
(n=109, 29%). This is probably due to the relatively low prevalence of progressive fibrosis in this group, combined 
with published information showing poorer treatment responses in genotype 1 patients. 11,30 The overall SVR 
was 32% (n=32) in participants infected during the 1977-79 anti-D outbreak and 34% (n=32) in other genotype 1 
database participants. Treatment uptake in participants infected during the second anti-D outbreak (1991-1994) has 
been extremely high (n=33, 87%). The percentage achieving SVR has also been very high (91%), even in comparison 
with other genotype 3 database participants (65%, n=42). 
Demographic characteristics, liver-related outcomes and treatment data for participants infected during each 
anti-D outbreak period are shown in table 24.
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Table 24. Summary of demographic characteristics, liver-related outcomes and antiviral treatment data by 
anti-D outbreak in chronically infected participants.
  1977-1979 Anti-D outbreak 1991-1994 Anti-D outbreak
Characteristic Number % Number %
Hepatitis C genotype Genotype 1 Genotype 3
Chronically infected with hepatitis C 378   38  
Median  age at infection (years) 28   30  
Median age at end of follow up (years) 59   46  
Median years since infection at end of follow up 32   16  
Mean duration RNA positivity (years) 32   6  
Alcohol intake        
Alcohol data available (highest reported) 368   37  
<14 units per week 337 91.6 32 86.5
15 to 40 units per week 17 4.6 2 5.4
>40 units per week or alcohol abuse in chart 14 3.8 3 8.1
Serum alanine aminotransferase levels        
Data available 377   36  
Normal 118 31.3 25 69.4
 Slightly elevated (from upper normal limit to <2.5 times upper 
normal limit) 183 48.5 7 19.4
More highly elevated (>2.5 times upper normal limit) 76 20.2 4 11.1
Liver disease severity        
Mild or no liver disease 205 54.2 19 50.0
Moderate 89 23.5 14 36.8
Severe 84 22.2 5 13.2
Outcomes        
Signs of liver disease 53 14.0 5 13.2
Cirrhosis 44 11.6 3 7.9
HCC 5 1.3 0 0.0
High fibrosis score on biopsy 70 18.5 2 5.3
Deceased 36 9.5 0 0.0
Liver-related disease directly caused death 11 2.9 0 0.0
Hepatitis C treatment        
Treated 109 28.8 33 86.8
Treated and treatment response available 99 26.2 33 86.8
SVR on peg-IFN & RBN - treatment naïve participants 19 (of 43) 44.2 4 (of 7) 57.1
Overall SVR on last treatment with any drug regimen 32 (of 99) 32.3 30 (of 33) 90.9
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Participants infected through blood transfusions or treatment for renal disease
Database participants infected through blood transfusions or treatment for renal disease had a high rate of HCV 
chronicity at diagnosis. RNA results were missing for three, but where results were available, 82% (n=273) were 
chronically infected and 18% (n=61) had cleared the HCV virus by this time.
The group of participants infected through blood transfusions or treatment for renal disease was the only patient 
cohort with a wide age distribution and significant proportions of both males and females, and both genotype 1 and 
3 infections. These characteristics facilitate the examination of the host and virus characteristics associated with 
liver disease severity. Logistic regression was used to model the factors that were independently and significantly 
associated with severe liver disease in this population (table 25).
High alcohol intake, older age at the end of latest follow-up, male gender, longer duration of infection and HCV 
genotype 3 were all found to be independently associated with severe liver disease (as defined on page 37) in 
chronically infected blood transfusion/renal patients (table 25). 
Table 25. Factors associated with severe liver disease in chronically infected participants infected through 
blood transfusions/treatment for renal disease - logistic regression model (n=236). 
Factors associated with having severe 
liver disease
Odds Ratio P-value 95% Confidence interval
Alcohol consumption      
 Non drinker/within recommended 
limits/moderately high
1 Reference Reference
 High (>40 units per week or alcohol 
abuse in chart) 3.6 0.005 1.49 - 8.78
Age at latest follow-up      
<50 years 1 Reference Reference
50+ years 4.0 <0.001 1.92 - 8.51
Gender      
Female 1 Reference Reference
Male 2.8 0.001 1.50 - 5.28
Duration of RNA positivity      
<20 years 1 Reference Reference
20+ years 2.5 0.004 1.35 - 4.72
Genotype      
Genotype 1 1 Reference Reference
Genotype 2 0.7 0.53 0.25 - 2.05
Genotype 3 2.5 0.005 1.32 - 4.75
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Participants infected through contaminated blood clotting factors 
Of the 165 database participants infected through blood clotting factors, 65% (n=107) were chronically infected with 
HCV at diagnosis and 22% (n=37) had no RNA results in their charts (figure 22). These patients had all died prior to 
RNA testing but had similar prevalence of serious liver-related outcomes to the chronically infected participants and 
it is likely that they were chronically infected with HCV when they died. The remaining 13% (n=21) had RNA results in 
their charts but had never tested positive. These participants showed no signs of serious liver-related disease by latest 
follow-up.
Thirty five percent (n=37) of the chronically infected participants and 84% (n=31) of those with no HCV RNA results 
were co-infected with HIV. It was difficult to ascertain the true effects of HIV co-infection on HCV disease progression 
as 66% (n=45) of the co-infected participants have died. However, 34% (n=23) of those who were HIV positive had 
clinical signs of liver disease by latest follow-up compared to 17% (n=13) of those who were HIV negative, even though 
they had a shorter median duration of follow-up (25 years compared to 28.5 years) (figure 22). High alcohol intake 
was also found to be associated with severe liver disease in HIV negative participants. Fifty six percent (n=5) of HIV 
negative participants with high alcohol consumption were classified as having severe liver disease by latest follow-
up compared to 17% (n=9) of those who had not had high alcohol intake. The effects of alcohol on liver disease 
severity was much less pronounced and not statistically significant in HIV positive participants, with 50% (n=4) of 
those with high alcohol consumption classified as having severe disease compared to 42% (n=13) of those without. 
However, as alcohol data were not available for all, these data comprise small numbers of participants and may not 
be representative. 
Death certificates were available for 42 of the 45 HIV positive participants who had died. The underlying cause of 
death was liver-related disease for ten and directly related to HIV infection for twelve. A further ten had causes of 
death relating to immunodeficiency, but the term HIV was not specifically mentioned on their death certificate. 
The underlying cause of death was classified as directly liver-related for 9 of the 25 HIV negative participants who had 
died, not liver-related for 15 and the death certificate was missing for the remaining patient. Of the nine liver-related 
deaths, four were caused by HCC, two were caused by cirrhosis, one was due to hepatorenal syndrome, one was due to 
hepatitis C and the remaining death was due to hepatitis B induced liver failure.
 
Fifty four (50%) participants chronically infected through blood clotting factors had received anti-viral treatment for 
HCV by latest follow-up. The percentage treated did not vary significantly by HIV status (49% HIV positive, 51% HIV 
negative). Treatment outcome was available for 52 and the percentage who achieved SVR on any drug regimen did 
not differ by HIV status (56% HIV positive, 50% HIV negative).
Twenty six treatment naïve participants were initially treated using peg-IFN and RBN combination therapy. Outcome 
was available for twenty four (12 HIV negative and 12 HIV positive) and SVR was achieved by 58% of HIV positive 
participants and 50% of HIV negative participants. The proportion who were genotype 1 was slightly higher in the HIV 
positive group (58% compared to 50%). The numbers treated were too low to reliably assess if treatment response 
in genotype 1 patients varied with HIV status, but treatment response rates look similar between HIV positive and 
negative clotting factor participants. The combined (HIV positive and negative) response rates on initial treatment 
with peg-IFN and RBN were 39% for genotype 1 participants and 73% for genotype 2/3 participants. These SVR rates 
were comparable to those achieved by participants infected through other means (41% SVR for genotype 1 and 73% 
for genotype 2/3). 
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Participants infected through clotting factors: Liver-related outcomes, HIV & alcohol
223 people identified as infected with hepatitis
C through blood clotting factors in Ireland
At the end of 2009: 74% participating in
hepatitis C database (n=165)
% with liver-
related outcomes
for chronically
infected
participants and
those with no
RNA results by
HIV status
Hepatitis C
status at
diagnosis
No cirrhosis,
HCC, liver-
related death
% with severe
liver disease by
HIV status &
alcohol
consumption
HIV positive:
median age at
infection with
hepatitis C
12 years
HIV negative:
Median age at
infection with
hepatitis C
17.5 years
HIV positive:
median age at end
of latest follow up
38.5 years
HIV negative:
median age at end
of latest follow up
47 years
Figure 22. Summary of hepatitis C infection and disease progression in participants infected 
through clotting factor, by HIV status.
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Clinical management and health service usage
Specialist health services and procedures
Since last follow-up, 40% (n=265) of ever chronically infected living participants and 21% (n=91) of those who were 
never chronically infected attended one or more specialist hospital services other than hepatology. The most common 
services used by chronically infected participants were haematology (9%), endocrinology (6%), rheumatology (5%) and 
psychiatry/psychology/counselling (5%) (table 26). As expected, a high proportion of participants infected through 
clotting factor attended haematology and physiotherapy services and a very high proportion of participants infected as 
a result of treatment for renal disease attended nephrology services. 
If health services or procedures are availed of privately and not discussed with a participant’s hepatologist they will not 
be recorded in a participant’s medical chart. Therefore they will be under-represented in the database. Services known 
to be commonly attended on a private basis include counselling, physiotherapy, chiropody and complementary and 
alternative therapies.
Table 26. Most common specialist services, other than hepatology, attended by living participants since the last 
round of follow-up data collection.
Most common services attended Ever chronically infected Never chronically infected
  Num % Num %
Haematology 63 9.4 14 3.3
Endocrinology 38 5.7 11 2.6
Rheumatology 32 4.8 9 2.1
 Psychiatry/psychology/counselling 31 4.6 1 0.2
Dermatology 30 4.5 6 1.4
Physiotherapy 28 4.2 15 3.5
Surgical 27 4.0 13 3.1
Ear, nose and throat 24 3.6 4 0.9
Cardiology 20 3.0 11 2.6
Neurology 17 2.5 11 2.6
Orthopaedic 17 2.5 4 0.9
Nephrology 16 2.4 2 0.5
Dietitian/nutritionist 15 2.2 4 0.9
Since last follow-up, 35% (n=233) of ever chronically infected living participants and 7% (n=28) of those who were never 
chronically infected underwent one or more liver-related procedures aside from liver biopsies. The most common liver-
related procedures were ultrasounds (32% of chronically infected living participants) and CT scans (5% of chronically 
infected living participants) (figure 23). The number of liver biopsies being carried out has been decreasing in recent 
years (figure 11). Because ultrasounds are less invasive and more acceptable to patients, it is likely that they are 
increasingly being used to monitor disease progression where possible. Some of the hepatology units have also started 
to use fibroscans to assess liver elasticity. Very little data were available to the end of 2009 on fibroscans. 
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Figure 23. Percentage of ever chronically infected living participants undergoing liver-related procedures, by year.
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Chapter 5  Discussion
This report describes the current health of a large group of people who were infected with hepatitis C virus through 
the administration of blood or blood products many years ago. Almost half of this population still have chronic 
hepatitis C infection. Despite this, the majority do not have evidence of serious liver disease after an average of more 
than 30 years of infection. However, the findings of this latest round of data collection have demonstrated further 
progression of liver disease in a small number of participants.
There is no evidence of cirrhosis or hepatocellular carcinoma in those participants who never developed chronic 
infection. In those who developed chronic infection, there has been a small increase in the proportion with cirrhosis, 
HCC and liver-related death compared with the previous round of data collection one year ago (17%, 4% and 6% 
respectively, compared with 14%, 3% and 5% one year ago).17
The factors found to be associated with progression of liver disease in the chronically infected database participants 
have been well described in the literature: male gender, duration of infection, older age, high alcohol intake.1,6,9 The 
odds of having severe liver disease were almost three times higher for males compared with females in the database 
population. 
Genotype 3 was also found to be independently associated with having severe liver disease in the database 
population, as noticed previously.17 The published data on the impact of HCV genotypes on fibrosis progression 
rates, development of cirrhosis, and the risk for HCC, have been conflicting.31 However, a recent study on a large 
dataset, The Swiss Hepatitis C Cohort, found that HCV genotype 3 was associated with accelerated fibrosis.32 
Conflicting results were reported from the UK HCV Register which found that type 1 infection is associated with 
greater aggressiveness than type 2 or 3 infections, with type 1 infection being independently associated with more 
advanced stages of liver disease on biopsies carried out by the Registry.33 
The most important factor in disease progression was alcohol intake. Participants who had high alcohol intake 
had more than five times higher odds of having severe liver disease compared to those without. This finding has 
been described in previous reports from the database.15,16,17 There is clear evidence from international sources 
that heavy alcohol use accelerates fibrosis progression and increases the risk of cirrhosis, HCC and end stage liver 
disease.34,35,36 The exact amount of alcohol required to increase the risk of disease progression in patients with HCV 
is unknown.
Although the number of participants with a history of high alcohol intake was small, accounting for only one third of 
those with severe liver disease, it is an important issue as it is one area where intervention is possible to reduce the 
risk of progression of disease. Patient information and education initiatives among people with HCV infection should 
focus on raising awareness of the risks associated with alcohol consumption. 
We would like to have better quality data on alcohol intake. Much of the alcohol consumption data on participants 
was last recorded many years ago. It is hoped that there may be more active recording of up to date information on 
alcohol consumption in the patient medical notes by the time of the next period of data collection. 
In general, those infected through anti-D immunoglobulin have demonstrated a more benign course than those 
infected through receipt of blood transfusion or clotting factors. This is likely to be related to the younger age at 
infection, female gender, relative lack of co-morbidity and lower alcohol use among the anti-D cohort.
Twenty two percent of participants with chronic infection have been successfully treated, having cleared the virus. 
Responses following treatment with combined pegylated interferon and ribavirin in database participants have been 
in line with internationally published figures, being 41% for genotype 1 and 73% for genotype 2 or 3 in treatment 
naïve patients.10,11 There is also evidence from serial biopsy results on successfully treated database patients that 
fibrosis scores have improved in over half of these and have not progressed in most of the others. The uptake of anti-
viral therapies has been highest in genotype 2 and 3 participants (69%), with only 35% of genotype 1 participants 
having been treated. This is understandable given the poorer response to treatment in genotype 1 infection.11 
However, most of those commencing treatment since 2007 have had genotype 1 infection. The recent addition of 
protease inhibitors into the management of genotype 1 infection will be captured in the next round of data collection 
and reported in the next report.  
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In recent years, there has been increasing use of non-invasive diagnostic techniques such as ultrasound, CT scan 
and fibroscans to monitor progression of liver disease. Many of the hepatology units in Ireland have now adopted 
the use of fibroscans. There was little information recorded on fibroscan results up to the end of 2009 and so this 
information is not included in the present report. However, we hope to have useful data on fibroscan findings in the 
next report.
Almost 90% of chronically infected participants attended their hepatology unit for follow-up within the past 1-2 
years. It is interesting to note that over half of those who never developed chronic infection had also attended the 
hepatology unit during that time. 
Depression was commonly recorded in the medical notes of many participants, particularly women, those 
with chronic infection and those who received anti-viral treatment. Many of these patients were on long-term 
medications for depression.  Fibromyalgia is also frequently diagnosed in database patients with chronic HCV 
infection, again more often in women than in men. An association between fibromyalgia and HCV infection 
was demonstrated in an American study of 90 HCV-infected patients, with 16% of cases being diagnosed with 
fibromyalgia while none of the control group were diagnosed with fibromyalgia.37 
Several amendments to the database are planned for 2013. These include new data fields for IL-28B genotype, 
and Child-Pugh and MELD scores (scores for severity of liver disease). In addition, the treatment section has been 
revised to capture details of new therapies, of adherence to treatment dose and schedule, and details of treatment 
responses at specified time points.
We hope that in the next round of data collection we will have useful information on genetic and metabolic factors 
affecting disease progression. The information on height and weight contained in patient medical notes to date has 
been limited and thus it has not been possible to examine the effect of BMI on disease progression in the database 
population. Data on steatosis were also infrequently available. We hope to be able to comment on these areas in 
future reports if the relevant data are recorded in the patients’ charts.
This report is based on the findings of the fourth round of data collection, and contains information on 
developments over the one year period since the previous data collection period. When the database was first set 
up it was envisaged that data would be collected every year. However, it is apparent now that little change in health 
status is likely to be evident in the space of one year and that annual data collection is not warranted. Therefore, 
the next round of data collection is planned for mid-2013 and will cover the three year period from 2010 to 2012 
inclusive.
The national hepatitis C database allows us to study the health of a large number of people who were infected with 
hepatitis C over 30 years ago. The participation rate in the database project is high at 77%. Eligible people who 
are not yet participants in the database may join at any time by contacting their hepatology unit. The database 
project team invites participants, health professionals and researchers to contact us with suggestions for further 
development or improvement of the database, and requests for information from the database. 
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Glossary of definitions, terms and 
abbreviations
Definitions
Case of hepatitis C for the purpose of this database
Any patient with one or more positive test results for hepatitis C, including positive RNA (PCR), line-immunoassay 
(RIBA/INNO-LIA) or EIA results, indeterminate line-immunoassay results and weak positive EIA results.
Confirmed positive case of hepatitis C
Any patient who had at least one positive RNA (PCR) result or at least one positive line-immunoassay (RIBA/INNO-
LIA) result.
Ever hepatitis C RNA positive (PCR positive)
Any patient who had at least one positive RNA (PCR) result
Definition of alcohol use in excess of recommended limits (as per guideline that was current at the time of this 
study)
More than 14 units (standard drinks) per week for females
More than 21 units (standard drinks) per week for males
A standard drink in Ireland (at the time of the study – 2009) equals 10gms of alcohol and is equal to a half pint of 
beer or a single measure of spirits or a small glass of wine. The limits of 14 and 21 standard drinks (spread out over 
the week) for women and men respectively are used as a general guide for low risk drinking.28
(Note: Low-risk drinking guidelines have since been revised and are now defined as 11 standard drinks for women 
and 17 standard drinks for men, per week).29 
Terms
Anti-D
Antibodies against rhesus D antigens. A small amount of the baby’s blood can enter the mother’s circulation during 
pregnancy, or larger amounts can enter during delivery. If the mother is negative for rhesus proteins and the baby is 
rhesus positive, the mother produces antibodies against the rhesus D antigens. These antibodies can pass through 
the placenta and damage the baby. The risk of disease is higher with subsequent pregnancies with rhesus positive 
babies. Anti-D immunoglobulin given during or after pregnancy prevents this.
Ascites
The accumulation of fluid in the spaces between tissues and organs in the abdominal cavity.
Autoantibody tests
Autoantibody tests detect antibodies, which normally fight infections and other foreign substance within the body, 
but are mistakenly attacking the body’s own cells, tissues or organs.
Blood clotting disorders (as used in this report)
Inherited blood disorders in which there is a defect in a factor essential for the clotting mechanism of the blood. 
These include haemophilia A (deficient in factor VIII), haemophilia B (deficient in factor IX), von Willebrand disease 
(deficient in von Willebrand factor) and deficiencies of factors V, VII or X.
Cirrhosis
Widespread replacement of liver tissue by fibrotic scar tissue and regenerative nodules, leading to progressive loss 
of liver function.
Confidence interval for an odds ratio
The width of a confidence interval provides a range of plausible values for the odds ratio in the population from 
which the data were sampled and gives an idea of the degree of confidence about the accuracy of an odds ratio. 
Database
A systematically arranged collection of computer data, structured so that it can be automatically retrieved or 
manipulated.
- 56 -
National Hepatitis C Database for infection acquired through blood and blood products HPSC
Early Virological Response 
Undetectable HCV RNA (< 50 IU/mL) by qualitative PCR or a ≥2 log drop in HCV RNA at week 12 by quantitative 
PCR
Extrahepatic manifestations of hepatitis C
Outside of, or unrelated to, the liver. Extrahepatic manifestations associated with hepatitis C include 
cryoglogulinaemia syndrome, glomerulonephritis, neuropathy, lymphoma, Sjögren syndrome, porphyria cutanea 
tarda, diabetes.
Fibrosis
Liver fibrosis refers to the accumulation of tough fibrous scar tissue in the liver.
Genotype testing
Hepatitis C genotype tests are used to determine which of the genetically distinct types of hepatitis C virus are 
present in the patient’s blood. Hepatitis C genotype is important in predicting response to anti-viral therapy. 
Health Amendment Act (HAA) card
The HAA card is given to people who contracted hepatitis C from the administration within the state of blood or 
blood products. They are entitled to a range of services under the Health (Amendment) Act 1996. 
Hepatic encephalopathy
Neuropsychiatric abnormality in the setting of liver failure. It is caused by toxic substances, which are normally 
removed by the liver, travelling in the blood to the brain.
Hepatitis C EIA (Enzyme Immunoassay) /ELISA (Enzyme-Linked Immunosorbent assay)
An assay that detects antibodies to specific hepatitis C antigens in a patient’s blood. The hepatitis C EIA test is 
usually used as an initial screening test for hepatitis C antibodies.
Hepatitis C PCR test (Polymerase Chain Reaction)
Test used to detect the presence of hepatitis C virus RNA (genetic material). A positive PCR result indicates an active 
infection with replicating virus.
Hepatocellular carcinoma (HCC)
Primary malignancy (cancer) of the liver.
Hepatomegaly
Enlarged liver.
Liver biopsy
A liver biopsy is a medical procedure involving the removal of a small piece of liver using a special needle. This is 
then examined under a microscope for signs of liver abnormality.
Liver function tests (LFTs)
Liver function tests are a group of blood tests which provide information about how the patient’s liver is functioning 
and may act as indicators of liver injury.
Mean (average)
The mean is a measure of central value that is used when values are normally distributed. The mean is calculated by 
dividing the sum of all the observations by the total number of observations. 
Median
The median is a measure of central value that is used when values are not normally distributed (skewed to one side). 
The median is obtained by arranging observations from lowest value to highest value and picking the middle value 
(divides the observations in half).
Meta-analysis
A meta-analysis combines the result of several studies on a particular topic to give an overall summary measure of 
effect.
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Multivariate logistic regression
Logistic regression is used to determine if the presence of, or level of, other characteristics affect the likelihood 
of a specific outcome of interest occurring. In a multivariate logistic regression model, each factor in the model is 
adjusted for the effect of the other factors on the outcome.
Odds ratio
The odds ratio is a measure of the odds of an event occurring in one group divided by the odds of it occurring in 
another group. An odds ratio of 1 indicates that the event is equally likely in both groups.
Oesophageal varices
Abnormally dilated and lengthened sub-mucosal veins in the oesophagus. These are usually a consequence of 
portal hypertension and may bleed.
Portal hypertension
High blood pressure in the portal vein that carries blood from the digestive tract to the liver. The most common 
cause is cirrhosis. Consequences can include ascites, hepatic encephalopathy, oesophageal varices and 
splenomegaly.
Positive predictive value
This is the proportion of all those who test positive who really have the disease or condition.
P-value
In statistics, a result is deemed significant if it is unlikely to have occurred by chance. The p-value is the probability 
of obtaining a result at least as extreme as the result obtained in the analysis, by chance alone. A p-value of 0.05 
indicates that there was a 5% (or 1 in 20) chance of obtaining the result by chance alone. If you are comparing 
the occurrence of a characteristic in two groups, a low p-value (<0.05) indicates that it is likely that there is a true 
difference in the value of, or odds of the occurrence of a characteristic in the two groups.
Rapid Virological Response
HCV RNA undetectable at week 4 of treatment
Recombinant immunoblot assay (RIBA)
An additional test for hepatitis C specific antigens in a patient’s blood. RIBA tests are usually performed after a 
positive EIA result and are used to confirm the presence of antibodies to the hepatitis C virus. A positive RIBA result 
is generally considered confirmation that a patient has been infected with hepatitis C, but cannot differentiate 
between past infection and current infection.
Renal
The term renal refers to the kidney.
Sensitivity
This measures how often a test turns out positive when it is being used on people who have the disease or condition.
Sicca/ Sjögren’s syndrome 
A chronic inflammatory disease that is characterized by dryness of mucous membranes especially of the eyes and 
mouth and by infiltration of the affected tissues by immune cells. There is a strong epidemiological association 
between Sjögren’s syndrome and hepatitis C infection.
Specificity
This measures how often a test turns out negative when it is being used on people who do not have the disease or 
condition.
Splenomegaly
Enlarged spleen.
Sustained virological response
The absence of detectable hepatitis C RNA in the serum as shown by a qualitative hepatitis C RNA assay with lower 
limit of detection of 50 IU/ml or less at 24 weeks after the end of treatment. 
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Abbreviations
ALT  Alanine aminotransferase (a liver enzyme)
Anti-HCV Antibody to hepatitis C virus
EIA  Enzyme immunoassay, a screening test for hepatitis C
EVR  Early Virological Response
HAA  Health (Amendment) Act
HCV  Hepatitis C virus
HIV  Human immunodeficiency virus
HPSC  Health Protection Surveillance Centre, formerly known as the National Disease Surveillance Centre
HSE  Health Service Executive
IBTS  Irish Blood Transfusion Service, formerly known as the Blood Transfusion Service Board
NDSC  National Disease Surveillance Centre, now known as the Health Protection Surveillance Centre
NICE  National Institute for Clinical Excellence
PCR  Polymerase chain reaction
RIBA  Recombinant immunoblot assay, a more specific hepatitis C test
RNA  Ribonucleic acid
RVR  Rapid Virological Response
WHO  World Health Organization
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Appendix A
Members of the National Hepatitis C Database Steering Committee
Dr Barbara Coughlan, UCD School of Nursing
Ms Anne Duffy, Irish Haemophilia Society
Ms Susan Gaughran, Transfusion Positive
Professor John Hegarty, St Vincent’s University Hospital (Alternate: Prof Suzanne Norris, St James’s Hospital)
Ms Lara Hynes, Department of Health and Children
Ms Helena Irish, St James’s Hospital
Ms Maura Long, Transfusion Positive
Mr Mark Murphy, Irish Kidney Association
Ms Niamh Murphy, Health Protection Surveillance Centre
Ms Joanne Deveney, Positive Action
Ms Michele Tait, Hepatitis C National Co-ordinator, Health Service Executive (Chair)
Dr Lelia Thornton, Health Protection Surveillance Centre
Ms Noeleen White, Positive Action
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Appendix B
Members of the National Hepatitis C Database Scientific and Technical Group
Prof Billy Bourke, Our Lady’s Children’s Hospital, Crumlin 
Prof Garry Courtney, St Luke’s Hospital, Kilkenny
Dr Orla Crosbie, Cork University Hospital
Prof John Crowe, Mater Misericordiae University Hospital
Prof John Hegarty, St Vincent’s University Hospital
Dr John Lee, University College Hospital, Galway
Ms Carol McNulty, St Vincent’s University Hospital
Ms Niamh Murphy, Health Protection Surveillance Centre
Prof Frank Murray, Beaumont Hospital
Dr Niamh Nolan, St Vincent’s University Hospital
Prof Suzanne Norris, St James’s Hospital
Prof Cliona O’Farrelly, Trinity College Dublin
Dr Lelia Thornton, Health Protection Surveillance Centre
Dr Stephen Stewart, Mater Misericordiae University Hospital
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Appendix C Data collection form for third year of follow-up
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Appendix D Biopsy scoring
Fibrosis scoring systems
Score
Original HAI or 
Knodell18
Modified HAI or 
Modified Knodell or 
Ishak19 or Desmet20
Scheuer21
International group of  
Hepatopathologists
0 No fibrosis No fibrosis None No fibrosis
1 Fibrosis portal expansion Fibrosis expansion of 
some portal areas, with 
or without short fibrous 
septa
Enlarged, fibrotic portal 
tracts
Fibrous portal expansion
2 Fibrosis expansion of 
most portal areas, with 
or without short fibrous 
septa
Periportal or portal-
portal septa with intact 
architecture
Portal septa with normal 
vascular relationships
3 Bridging fibrosis (portal-
portal or portal-central 
linkage)
Fibrosis expansion of 
most portal areas, with 
occasional portal to por-
tal bridging
Fibrosis with architectural 
distortion but no obvious 
cirrhosis
Distorted structure or in-
complete cirrhosis (focal 
nodules)
4 Cirrhosis Fibrosis expansion of 
portal areas, with marked 
bridging (portal to portal 
as well as portal to 
central)
Probable or definite cir-
rhosis
Cirrhosis, probable or 
definite
5 Marked bridging with 
occasional nodules (in-
complete cirrhosis)
6 Cirrhosis, probable or 
definite
The grade of inflammation on biopsy was categorised as:
Normal, mild inflammation, moderate inflammation or severe inflammation
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Appendix E Contact Information
Support Groups
Positive Action
56 Fitzwilliam Square, Dublin 2. Tel: 01-676 2853, Fax: 01-662 0009
www.positiveaction.ie
Transfusion Positive
3 Clanwilliam Square, Dublin 2. Tel: 01-639 8855. Fax: 01-639 8856
www.transfusionpositive.ie
Irish Haemophilia Society
First Floor, Cathedral Court, New St, Dublin 8. Tel:01-657 9900, Fax: 01-657 9901, 
Email: info@haemophilia.ie, Website: www.haemophilia.ie 
Irish Kidney Association
Donor House, Block 43a Park West, Dublin 12. Tel: 01-620 5306, Fax: 01-620 5366, Locall: 1890-543 639, 
E-mail: info@ika.ie, Website: www.ika.ie
Specialist Centres
Beaumont Hospital
Hepatology Unit, Beaumont Road, Dublin 9. Tel: 01-809 2220/01-809 3000
Mater Misericordiae University Hospital
Hepatology Unit, 55 Eccles St., Dublin 7. Tel:01-803 2048/01-803 2000
St. James’s Hospital
Hepatology Unit, James’s St., Dublin 8. Tel: 01-410 3417/01-410 3000
St. Vincent’s University Hospital
Hepatology Unit, Elm Park, Dublin 4. Tel: 01-209 4248/01-269 4533
Our Lady’s Children’s Hospital
Hepatology Unit, Crumlin, Dublin 12. Tel: 01-409 6742/01-409 6100          
 
Cork University Hospital
Hepatology Unit, Wilton, Cork. Tel: 021 492 2274/021-454 6400
University College Hospital
Hepatology Unit, Newcastle Road, Galway. Tel: 091-544 370/091-524 222
St. Luke’s Hospital
Hepatology Unit, Kilkenny. Tel: 056-778 5329/056-778 5000
Liaison Officers
Ms Michele Tait, National Co-ordinator of Hepatitis C Services, Health Service Executive, 
Mill Lane, Palmerstown, Dublin 20. Tel: 01 620 1712 or 01 620 1750
HSE Dublin North East
Dublin North/North West/North Central, Cavan, Monaghan, Louth & Meath 
Mr Larry Bathe, Health Service Executive, Primary Care Unit, Railway Street, Navan, Co Meath  Tel: 046 9076451
National Hepatitis C Database for infection acquired through blood and blood products HPSC
HSE Dublin Mid Leinster 
Dublin South/ South West/West/ East Coast, Kildare & Wicklow 
Ms Michelle Hayes, Health Service Executive, Mill Lane, Palmerstown, Dublin 20 Tel 01 6201840 
Laois, Longford, Offaly & Westmeath
Ms Elaine Barry, Primary Care Unit, Health Service Executive, Springfield, Mullingar, Co Westmeath. 
Tel: 044 938 4429
HSE West  
Clare, Limerick & Tipperary North
Ms Ellen Rush, Tyone Health Centre, Tyone, Nenagh, Co Tipperary. Tel: 067 46449
Leitrim, Sligo & Donegal
Mr Colin McCann, 1st Floor, County Clinic, St Conal’s Hospital, Letterkenny, Co Donegal. Tel 074 9104698 
 
Galway, Mayo & Roscommon
Mr Richard Broderick, Health Service Executive Primary Care Unit, Merlin Park Regional Hospital, Galway. 
Tel: 091 775673
HSE South 
Carlow, Kilkenny, Tipperary South,Waterford & Wexford
Ms Anne Bambrick, Primary Care Unit, Health Service Executive, Lacken, Dublin Road, Kilkenny, Co Kilkenny. 
Tel: 056 7784296
 
Cork/Kerry
Mr Donal Murphy, Primary Care Unit, Health Service Executive, 26/27 South Mall, Cork. 
Tel: 021 4921872 / 021 492 1871
For all queries that cannot be resolved at local level and within the hospital services:
Ms Michele Tait, Health Service Executive, Mill Lane, Palmerstown, Dublin 20. Tel: 01 620 1712
 
Relevant National Agencies
Health Protection Surveillance Centre,
25-27 Middle Gardiner St, Dublin 1. Tel: 01-8765300. Email: hcvdatabase@hpsc.ie
Website: www.hpsc.ie, Database website: www.hcvdatabase.ie
National Centre for Hereditary Coagulation Disorders (NCHCD)
St James’s Hospital, James’s St., Dublin 8. Tel: 01-416 2141
Irish Blood Transfusion Service
National Blood Centre, James’s St., Dublin 8. Tel: 01-432 2800
National Virus Reference Laboratory
UCD, Belfield, Dublin 4. Tel: 01-716 1323
Consultative Council on Hepatitis C
2nd Floor HSE Offices, Mill Lane, Palmerstown, Dublin 20. Tel: 01-620 1708
Email: cchepc@health.irlgov.ie, Website: http://www.consultativecouncilonhepc.ie/
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p
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b
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 l
ev
el
s 
(a
nt
ib
o
d
y 
p
o
si
ti
ve
, 
b
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at
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p
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 b
e 
in
cl
ud
ed
 i
n 
th
e 
d
at
ab
as
e 
b
eg
an
 i
n 
20
05
. 
Fo
llo
w
 u
p
 d
at
a 
is
 c
o
lle
ct
ed
 
ea
ch
 y
ea
r 
fr
o
m
 p
at
ie
nt
s’
 m
ed
ic
al
 n
o
te
s,
 a
nd
 
th
e 
th
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is
 n
o
w
 
co
m
p
le
te
d
. 
 N
am
es
 a
nd
 a
d
d
re
ss
es
 a
re
 n
o
t 
co
lle
ct
ed
 i
n 
th
e 
d
at
ab
as
e 
an
d
 t
he
re
 i
s 
no
 
d
ire
ct
 c
o
nt
ac
t 
m
ad
e 
w
it
h 
p
at
ie
nt
s.
 
P
le
as
e 
co
nt
ac
t 
w
it
h 
yo
ur
 h
ep
at
o
lo
g
y 
un
it
 
o
r 
p
at
ie
nt
 s
up
p
o
rt
 g
ro
up
 i
f 
yo
u 
w
is
h 
to
 
p
ar
ti
ci
p
at
e 
an
d
 h
av
e 
no
t 
ye
t 
g
iv
en
 y
o
ur
 
co
ns
en
t.
  
W
ha
t i
nf
or
m
at
io
n 
is 
co
lle
ct
ed
 in
 th
e d
at
ab
as
e?
In
fo
rm
at
io
n 
is
 c
o
lle
ct
ed
 o
n 
th
e 
so
ur
ce
 o
f 
in
fe
ct
io
n,
 c
ur
re
nt
 s
ta
te
 o
f 
he
al
th
, 
us
e 
o
f 
he
al
th
 
se
rv
ic
es
, l
iv
er
 b
io
p
sy
 a
nd
 o
th
er
 t
es
t 
re
su
lt
s,
 a
nd
 t
re
at
m
en
t.
  
Th
e d
at
ab
as
e p
op
ul
at
io
n
• T
he
 t
o
ta
l n
um
b
er
 o
f 
p
ar
ti
ci
p
an
ts
 in
 t
he
 d
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b
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b
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ra
ns
fu
si
o
ns
 o
r 
tr
ea
tm
en
t 
fo
r 
ki
d
ne
y 
d
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at
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l c
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d
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d
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b
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 c
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l m
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p
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b
et
es
 
w
as
 
hi
g
he
r 
th
an
 
fo
r 
th
o
se
 
no
t 
ch
ro
ni
ca
lly
 in
fe
ct
ed
.
• 
 Th
e 
sp
ec
ia
lis
t 
ho
sp
it
al
 s
er
vi
ce
s,
 o
th
er
 t
ha
n 
he
p
at
o
lo
g
y,
 
m
o
st
 
co
m
m
o
nl
y 
at
te
nd
ed
 
b
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p
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 p
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se
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 p
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 c
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ra
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